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ABSTRACT 
 
AIM :  
 To compare the  efficacy, safety and cost effectiveness of oral 
Doxofylline and Theophylline for mild to moderate persistent bronchial asthma 
patients. 
 
MATERIALS AND METHODS:  
 A Randomized prospective, open labeled comparative study of 1 year 
(Jul2014-Jun2015) duration was conducted in 186 patients who were attending 
the thoracic medicine outpatient department of Chengalpattu Medical College 
satisfying the inclusion and exclusion criteria after obtaining ethical clearance. 
 
METHODOLOGY:  
 The study subjects were randomly allocated into two groups. Group 1 
patients were treated with Doxofylline 400mg once daily and group 2 patients 
were treated with Theophylline twice daily.  Demographic data, history, 
clinical examination and details of drug prescription by the treating physician 
were recorded in the study proforma. Relevant lab investigations were done at 
the beginning and at the end of the study.  The patients were followed up for 12 
weeks.  The schedule of patient visit is as follows Visit 1 for initial or baseline 
assessment and follow-up at 4, 8 & 12 weeks. 
 
STATISTICAL ANALYSIS:  
 The data collected were analyzed using Student t test (two tailed, 
independent) to find the significance of study parameters on continuous scale 
between two groups. Chi-square/ Fisher Exact test was used to find the 
significance of study parameters on categorical scale between two or more 
groups. 
  
 RESULT:  
 Doxofylline was better than deriphylline in subjective parameters of 
asthma control test questionnaire and subjective rating of asthma control. 
Doxofylline had equal efficacy as that of deriphylline in spirometric parameters   
(p ≤ 0.001). Doxofylline was significantly safe compared to deriphylline as 
inferred from lesser incidence of adverse drug reactions. Adverse reactions are 
encountered in 10% of doxofylline and 22% of deriphylline group.  
Deriphylline was the cheaper and cost effective methylxanthene for the 
treatment of bronchial asthma in developing countries at population level. 
Doxofylline even though costlier had better safety profile with less adverse 
reactions compared to deriphylline. It can be used as an individual based 
approach in asthma management.  
 
CONCLUSION:  
 Doxofylline is a newer methylxanthine with few adverse effects and 
equal efficacy as compared with deriphylline. It is a better alternative in the 
management of bronchial asthma. 
 
KEY WORDS:  
 Bronchial Asthma, Methylxanthene, Doxofylline, Deriphylline, 
Efficacy, Safety, Cost Effectiveness.  
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INTRODUCTION 
 
 Asthma is a heterogeneous  disease usually characterized  by  chronic 
airway  inflammation .It is defined  by the history of respiratory  symptoms  such  
as  wheeze, shortness  of  breath, chest tightness and  cough  that  vary  over  in 
time  and  intensity,  together  with  variable  respiratory  airflow  limitation.1, 2 
 
 The prevalence of asthma is 1-18%1 in the world. It contributes 1% of the 
total disease burden of the world3. Genetic factors, allergens, infection, 
occupational  exposure,  smoking  and  air  pollution  trigger  the development  
of  bronchial  asthma. 
 
 Treatment  of asthma  is  directed towards the  control  of  symptoms  and  
bringing  down  the  frequency  of  acute  attacks  with  fewer  side  effects. It 
also aims to minimize remodeling of airways. 
 
 The  drugs available  for  asthma  are  categorized  as  controllers, 
relievers  and  add  on  therapies. Controllers are used to bring down 
inflammation in airways, decrease the symptoms and minimize acute attacks. 
These include steroids by both inhalational and systemic route, leukotriene 
receptor antagonist, methylxanthines and anti IgE antibody. Relievers are used to 
relieve symptoms whenever   needed. Relievers also play a role in preventing 
exercise induced asthma. Short acting β2 agonists, anticholinergics in inhaled 
route, and theophylline are used as reliever medications. When  the  patient’s  
symptoms  persist  even  with  adequate  management , add on  therapies are  
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used. Tiotropium, anti  IgE antibody ,  Leukotriene  receptor  antagonist  are  
given  as  add  on  therapy.1, 2 
 
 Methylxanthines are phosphodiesterase inhibitors. Theophylline is a 
widely used drug belonging to this group. It has bronchodilatory, anti-
inflammatory, mucoregulatory, immune modulatory steroid sparing properties. It 
has a  narrow  therapeutic  index  with  cardiac, gastrointestinal  and  CNS  side  
effects  which  contribute  non  adherence  to  treatment6, 7. 
 
 Doxofylline , another  methylxanthine  has  fewer  side  effects  and  
bronchodilation  comparable  to  theopylline.  They  provide  better  asthmatic  
control  and  decrease  the  frequency  of  acute  attacks7. As   the  prevention  
and   management  of  asthma  depends  more  on  pharmacotherapy, there  is  a 
quest  for  bronchodilatory    medications  with  few  adverse  effects.          
Methylxanthines   are  the first  line  of  drugs  for  management  of  mild  to 
moderate  bronchial   asthma  as  per  Cochrane  group7.  
 
 For  choosing  among  the  asthma  treatment  options  at  population-
level,  pharmaco- economics  plays  an  absolute  role. Cost  effectiveness 
analysis   considers  the  cost  of    medications, effectiveness of the  treatment, 
safety  data  and  serves  to adapt   the  best  choice  for  the   patients. This  
study  is  focused  to  compare the  efficacy,  safety  and  cost  effectiveness  of  
Doxofylline   over  Theophylline   in  mild  to  moderate  persistent  bronchial  
asthma  patients. 
  
Aims  
and   
Objectives 
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AIM & OBJECTIVES 
 
• To  compare  the  efficacy  of  oral  Doxofylline  and Theophylline  for  
mild  to  moderate  persistent  bronchial  asthma  patients. 
 
• To understand the safety profile of Doxofylline and Theophylline. 
 
• To analyse the cost effectiveness of Doxofylline over Theophylline.    
 
  
 Review   
Of  Literature 
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REVIEW OF LITERATURE 
 
HISTORY:  
 The word "ASTHMA" is derived from Greek which means a condition 
involving difficulty in breathing. British adapted "ASMA" from Greek which 
means "ASTMA"and then the final form "ASTHMA" evolved. 
 
 It was Hippocrates (460-370Bc) who noticed the constructive effect of 
"ASTHMA". According to him, the various causes for the onset of this disease 
were climate, level of moisture and occupation. He compared it with epilepsy 
and distinguished asthma by its nature of occurrence due to external influence. 
 
Later Areatus (2-3 century) explained the two forms of asthma as 
 a breathing difficulty caused by activities such  as running 
 a constructive breathing difficulty due to humidity and low temperature8. 
 
 During the 12th century, the Egyptian physicians recommended the 
details of the patient’s physical status, diet, hygiene, environment, personal 
attitude and behaviour pattern had to be known for better management of the 
disease. It was strongly believed that the mental condition of the patient will 
influence his physical well being9. 
 
 More prime facts were unfolded in further studies. JEAN BAPTISTE 
VAN HELMONT (1577-1644) pointed out bronchi as the major throne of 
asthma. Osler explained the pattern of asthma as a result of dust inhalation and 
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fish intake8. Henry Hyde Salt, in his work, "On Asthma, its Pathology and 
Treatment"(1860), discriminated asthma from dyspnoea. He described the 
childhood asthma as a different form. The inhalation of dust, fur, hay etc. are 
other contributors towards the disease9. 
 
 The definition of bronchial asthma given by the American Thoracic 
Society, New York in 1862 states that asthma is a  hyper  responsiveness of 
trachea  and bronchi to multiple factors which result in airway narrowing of 
variable severity either spontaneously or due to therapy. 
 
 It was in the year 1900, adrenaline was identified as the drug for asthma. 
It relaxes smooth muscles of the respiratory tract. Regular use of adrenaline for 
asthma management came into practice. During 1906, the view of etiology of 
asthma as anaphylaxis and allergy was put forward. 
 
 From 1930, theophylline was used for asthma treatment. From 1967, the 
management included short acting β 2 agonist. In 1968, SIR JOHN FLOYER, 
through his work, "A TREATIES OF ASTHMA", brought forward the fact of 
bronchoconstriction. He pointed out different types of asthma like continuous, 
periodic and convulsive. He also stated that environmental factors provoke 
asthma. 
 
 The discovery of sodium chromoglycate in 1968 made a new path in this 
disease. Using   inhaled steroids, anti-inflammatory effect was brought in the 
year 1972. In 1982, Nobel Prize was awarded for the discovery of slow reacting 
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substance, which played a role in mediating asthma. The discovery of 
Leukotriene receptor antagonist in 1990 helped in treating chronic asthma9. 
 
 Omalizumab, anti-IgE antibody is a recombinant humanized monoclonal 
antibody10. It interrupts the reaction between IgE and inflammatory mediators, 
preventing crosslinking and degranulation. 
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EPIDEMIOLOGY 
 
MAGNITUDE OF THE DISEASE: 
 Asthma is a major health hazard which affects the people of all age 
groups. The current asthmatic population is around 300 million worldwide3. In 
some geographical region, the prevalence exceeds 10% in adults and 30% in 
children. India harbours about 15-20 million asthmatics. The estimated 
prevalence of asthma in India is around 4% - 5% in adults and 10%-15% among 
pediatric population12, 13 .In Tamilnadu, the prevalence is around 4.84%13, 14 
 
THE SOCIO-ECONOMIC BURDEN: 
 As the global prevalence of asthma has an increasing trend, the socio-
economic burden due to this illness is severe. It imparts a heavy blow on the 
society by decreasing in productivity, absenteeism in the work place, increase in 
hospitalisation, decrease in the longitivity of lives15. The direct and indirect costs 
for asthma care is evaluated and found to be more than that of TB/HIV AIDS 
management. 
 
AETIOLOGY: 
 Asthma is multifunctional in origin .It arises from complex interaction of 
genetic and environmental factors. The airway inflammation seems to occur 
when genetically susceptible individuals are exposed to certain environmental 
factors .Additional environmental determinants are the concurrent exposure to 
cigarette smoke, atmospheric pollutants and respiratory tract infections18.    
  
  
8 
 
THE FOLLOWING ARE THE RISK FACTORS: 
 GEOGRAPHICAL DISTRIBUTION: 
Asthma is more widely distributed in the West compared to the other 
parts of the world. 
 
 AGE AND SEX:  
Asthma is more commonly diagnosed during infancy. Childhood asthma 
occurs frequently in boys than girls; but in adults, the incidence reverses. 
 
 ETHINICITY: 
The blacks have higher morbidity and mortality than whites due to               
asthma. 
 
 SMOKING: 
Asthma occurs more often in children born to mothers who have smoking 
habit. 
 
 AIR POLLUTION: 
Global warming increased concentration of harmful gases in air. 
Occupational exposure   contributes to the rise in asthma prevalence. 
 
 ATOPY  AND ALLERGENS: 
Atopy is a major risk factor .Exposure to allergens in the early age of life 
is associated with higher incidence of asthma. Family history of any form 
of allergy and elevated IgE levels are more in favour of asthma24. 
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 INFECTIONS AND INFESTATIONS: 
Few bacteria, viruses and parasites impart an increase in serum IgE level. 
(e.g.) Respiratory syncytial virus, Measles virus, Vaccine against 
pertussis21. 
 
 DIET 
Occurrence of allergy in the early life is reduced when the baby is 
breastfed. Obese individuals are more prone for asthma. Omega 3 fatty 
acid in the diet and antioxidants reduce the risk of asthma. 
Lot of stimuli, both constitutional and environmental are involved in 
bronchial asthma triggering. 
 
The common triggers are the following: 
 Allergens 
 Drugs 
 Occupational exposure 
 Smoking 
 Infections 
 Stress 
 Exercise associated 
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Figure 1: Triggers Of Asthma 
 
ALLERGENS: 
 The following are the array of allergens which trigger the asthmatic 
attack: house dust mites, are found in high concentration in carpets, soft 
furnishings and bedding. Pet derived allergens are widespread in homes where 
dogs, cats or cattle are kept. Feathers also induce a kind of allergen. Fungal 
spores and antigens from cockroaches play an immense role in spreading 
allergens19. 
 
DRUGS: 
 Beta blocking drugs can induce bronchoconstriction in asthmatics. A 
small percentage of asthmatics develop bronchoconstriction when given 
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salicylates or non-steroidal anti-inflammatory drugs. These drugs block 
arachidonic acid metabolism down the prostaglandin pathway diverting it to the 
leukotriene pathway. Verapamil, piperazine, cimetidine also trigger asthma. 
 
OCCUPATIONAL EXPOSURE: 
 Many agents encountered in the work place may induce asthma. The 
compounds include isocyanates, epoxyresins, persulphates, hardwood dusts, 
grain dust etc,. 
 
ENVIRONMENTAL AND AIR POLLUTION: 
 Increasing prevalence of asthma is attributable to atmospheric pollution 
which plays a role in triggering exacerbations of pre-existing of asthma. 
Nitrogen dioxide, ozone, sulphur dioxide and airborne particulates have acute 
adverse effects on asthma during air pollution episodes20. Motor vehicle 
emissions, power stations, fuel burning industries, gas cookers, kerosene heaters, 
burning of fossil fuels, domestic coal burning, block smoke, pollens, allergens 
are particularly associated with asthma. 
 
SMOKING: 
 Cigarette smoking is associated with increased levels of Ig E and with 
increased sensitization to certain occupational allergens in particular. Maternal 
smoking during pregnancy increases the risk of developing atopic disease in 
infancy. Passive exposure to cigarette smoke at home has an adverse effect on 
asthma and other respiratory diseases among children in particular. 
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INFECTIONS: 
 Many respiratory infections like influenzaA, mycoplasma pneumonia, 
Chlamydia pneumonia, respiratory syncytial virus etc. provide a transient 
increase in airway responsiveness in normal individuals and in asthmatics21, 22. 
 
EXCERSIE INDUCED: 
 Hyperventilation during exercise along with respiratory heat exchange 
and water loss provoke the occurrence of bronchoconstriction and bronchial 
asthma. The bronchoconstriction due to exercise depends on the strength of the 
stimulus and also on the quality of nonspecific airway responsiveness23. 
 
STRESS: 
 The emotional and cognitive factors induce the T helper cytokines. When 
the individual is provoked by a stimuli, inflammatory response is generated 
resulting in prolonged duration and more frequent severe asthmatic attack. The 
other mechanism suggested is vagal mediated response promoting 
bronchoconstriction. 
 
CO-EXISTING DISORDERS: 
 There are few conditions which occur along with asthma. Management of 
these disorders are essential for better control of asthma. 
 
1. RHINITIS AND SINUSITIS: 
 More than 50% of the asthmatics have co-existing rhinitis and sinusitis. 
Proper   management of allergic rhinitis is important25, 26. 
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2. GASTRO-OESOPHAGEAL REFLUX DISEASE: 
 GERD occurs in about 75% of asthma patients. The mechanism 
implicated are bronchoconstriction as a result of lower esophageal sensory 
stimulation and micro aspiration27. Treatment of GERD is essential. 
 
3. OBESITY: 
 Obesity triggers the expression of inflammatory mediators responsible for 
airway constriction. Obesity is directly proportional to the rate of asthma 
occurrence28. 
 
PATHOGENESIS OFASTHMA:    
 
Figure 2: Pathogenesis Of Asthma 
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 Asthma is a spectrum of disorders with airway inflammation along with 
hyper responsiveness resulting in airway obstruction. Proper understanding of its 
mechanism of development is necessary for its management. 
 
GENETICS OF ATOPY AND ASTHMA:    
 There is strong evidence for the hereditary contribution to the etiology of 
asthma24. Asthma and atopy run in families. First degree relatives of asthmatics 
have a significantly higher prevalence of asthma than the relatives of non 
asthmatic patients. 
 
 Atopy is a constitutional tendency to produce significant amount of IgE 
on exposure to small antigens. Atopic individuals demonstrate positive reactions 
to antigens on skin prick test and have a high prevalence of asthma, allergic 
rhinitis, utricaria and eczema. 
 
 The genetic contribution to asthma is complex involving polygenic 
inheritance and genetic heterogeneity. 
 
 Asthma has an autosomal recessive inheritance with dominant and co-
dominant expression. The below mentioned are some suggested polymorphisms 
seen in the genes of asthma patients: chromosome 5 has genes representing IgE, 
Interleukin 3, interleukin 4, interleukin 5, interleukin 9, interleukin 13 and GM-
CSF which play a vital role in asthma. 
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 Chromosome 2 encodes the atopy gene which is represented by FcER 1 
region. FcER 1 is present on basophils, mast cells and dendritic cells.  Its 
function is to increase the uptake of antigen and its expression. 
 
 Chromosome 12 provides a connection between asthma and atopy by the 
way of   gamma   interferon and nitric oxide production. 
 
 Chromosome 6   harbours the gene encoding HLA class II and cytokine 
TNF α.  These are involved in the susceptibility and severity of asthma. 
 
 Chromosome 14 and 7 encodes the T cell receptor proteins which 
influence the IgE function18. 
 
BRONCHIAL HYPERRESONSIVENESS: 
 Most of the symptoms and signs of asthma are due to bronchial hyper 
responsiveness. There is an altered response in asthma patients compared with 
normal subjects to the external allergens. This response can be measured with 
the help of bronchial provocation test. There is a direct link among the severity 
of the disease, the need of the drugs and provocation concentration. This test 
measures the only one important   component of asthma and serves as a tool for 
assessing asthma control30. 
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INFLAMATORY CELLS EXPRESSED IN ASTHMA:  
 The range of cells associated with asthma include not only mast cells, 
eosinophils, cytokines, T – lymphocytes but also structural cells like epithelial 
cells, endothelial cells, smooth muscle cells and fibroblasts32. 
 
MAST CELLS:   
 Mast cells are seen on entire respiratory tract.  They are clustered in the 
sub mucosal and epithelial surface of the bronchi.  Mast cells release a cascade 
of preformed mediators as well as produce new mediators in a time interval of 
30 minutes.  Histamine, mast cells proteases particularly tryptase,  newly formed 
mediators like prostaglandin D2, leukotriens,   cytokines IL 4, IL5, IL6   and 
TNF α which are contributed by mast cells form the central mechanism34. 
 
BASOPHILS: 
 The only other cells to secrete histamine are basophils.  Basophils can be 
triggered not only by Ig E mediated factors but also other substances such as IL 
1, IL -3, IL – 8, RANTES, PAF etc.  Their sensitivity to anti IgE is 100 times 
higher than that of mast cells.  Basophils produce LTC 4,   and they contribute 
more to the allergies occurring in skin32. 
 
EOSINOPHILS: 
 Eosinophilia particularly in the airway mucosa is linked with the 
diagnosis of asthma.   Their count correlates with the disease activity.  The 
granules present in the eosinophils such as eosinophil cationic protein, major 
basic protein, eosinophil peroxidase, eosinophil derived neurotoxin contribute to 
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the cytotoxic action of eosinophils.  Eosinophils are the generators of oxygen 
free radicals, sulphidopentide, leukotrienes lineage of cytokines which induce 
bronchospasms and inflammation36. 
 
NEUTROPHILS: 
 Infiltration of neutrophils in the airways are observed in patients having 
severe asthma and those exposed to ozone and sulphur dioxide and also smokers.  
Their role in causing asthma or contributing to the disease severity is not clear19.   
 
MONOCYTES AND MACROPHAGES 
 These are the major cell types present in bronchial lumen.  They have low 
affinity IgE Fc receptors which contribute to the release of mediators.  They 
have significant role in atopic asthma.38 
 
DENDRITIC CELLS 
 Dendritic cells have MHC class II molecules and they serve as prime 
antigen presenting cells in the airways.  They induce T- Cell differentiation and 
Th 2 cytokine formation and the cascade of inflammatory events occur.37 
 
LYMPHOCYTES 
 There are more number of T lymphocytes in asthma than B lymphocytes.  
Ig E mediated cellular activities in asthma rely upon T – cell activation.  The 
activated T cells also regulate mast cells, eosinophils, epithelial cells and 
fibroblasts.  The T lymphocytes are divided into CD4+ CD8+ Cells.  The CD 4 + 
are also called as helper cells, which are further classified in to Th1 and Th2.  
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The Th 2 cells play a vital role in triggering IgE mediated inflammatory 
reactions, while Th1 inhibit IgE and have an opposite effect.33 
 
AIRWAY SMOOTH MUSCLE CELLS 
 The smooth muscle cells of air passages are contracted in response to 
inflammatory mediators.  The other events that occur as a consequence of 
inflammation are activation, proliferation, hypertrophy of the smooth muscle 
cells.34 
 
EPITHELIAL CELLS 
 The epithelial cells participate in the inflammatory process and this 
induces damage to the epithelium.  The repair of this event which is abnormal in 
the most of the asthmatic individuals, further contribute to the obstruction of 
airways.39 
 
NEURAL MECHANISM OF ASTHMA 
 There exists   an inter relationship between the inflammatory pathways 
and the neuronal aspects of airway function.  The mediators of inflammation 
modulate the effect of neural tissues.  On the other hand, the neuro transmitters 
influence the process of inflammation.   
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Figure 3: Neural Networks In Asthma 
 
Cholinergic, adrenergic, NANC neural networks exert their control over airways.  
The cholinergic control of respiration is exerted through: 
1. Increased vagal tone 
2. Triggering of airway sensory receptors resulting in reflex 
bronchoconstriction. 
3. Enhanced acetylcholine release from parasympathetic ganglia as well as 
post ganglionic neurons. 
 
 Adrenergic system exerts its effects through sympathetic nerves via α and 
β receptors. These nerves indirectly control cholinergic transmission through the 
prejunctional α or β receptors.  Adrenergic influence is vital in exercise induced 
asthma and when asthma is triggered by cold air. The non adrenergic, non 
cholinergic nerves (NANC) are believed to release vasoactive intestinal peptide 
and nitric oxide. These neuro transmitters counteract the bronchial smooth 
muscles contractions mediated by acetyl choline.  There is evidence that 
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inflammatory cells release superoxide which degrade VIP.  This contributes to 
increased bronchial contraction.29, 31 
 
AIRWAY NEUROPEPTIDES: 
 The sensory nerve fibres (C) which are unmyelinated are present in the 
airway.  
 
 They harbour various neuropeptides like substance P, neurokinin (NK), 
calcitonin gene related peptide (CGRP) 
 
 Due to the damage of the airway epithelium in asthma, the sensory nerve 
endings are exposed which may trigger the release of this neuro transmitters and 
result in the airway inflammation.32 
 
AIRWAY REMODELLING: 
 Due to chronic inflammation and structural changes occur in the airway 
of asthmatics, these changes are referred as airway remodelling.  
 
Figure 4: Airway Remodelling 
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GROWTH FACTORS IMPLICATED IN AIRWAY REMODELLING: 
 The damaged airway epithelial cells produce many growth factors such as 
transforming growth factors (TGF) α, β endothelin (ET).  Insulin like growth 
factor (IGF) basic fibroblast growth factor b (FGF), platelet derived growth 
factor (PDGF).The activated fibroblast release connective tissue growth factor 
(CTDGF), vascular endothelial growth factor (VEGF), Keratinocyte growth 
factor (KGF) etc. which play a role in airway remodelling.31 
 
CONSEQUENCE OF AIRWAY REMODELLING: 
 Airway remodelling, which involves all the layers of airway wall results 
in the following modifications:   
 
1. Increasing in sloughing of the epithelium, leading to loss of integrity. 
2. Exposure of the nerve endings.  
3. Hypertrophy and hyperplasia of airway smooth muscles. 
4. Destruction of Elastic tissues. 
5. Increase in the number of blood vessels in the mucosa. 
6. Micro vascular leakage. 
7. Sub mucosal edema of the airways. 
8. Mucus hyper secretion muscle plugs. 
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PATHOLOGY 
 The main pathology involved in asthma is airway thickening and 
remodelling which leads to narrowing of the airway lumen.30 Apart from 
constriction of airways, bronchial congestion and edema are seen in the 
asthmatic.  In chronic asthma there is inflammatory cells infiltration.  
Eosinophilia is consistently seen in asthmatic which is triggered by T – helper 
cells (CD4+). The role of mast cells are evident in immediate type of 
hypersensitivity reaction in asthmatics.34 
 
 
Figure 5: Pathology Of Asthma. 
 
SPUTUM & BRONCHIO ALVEOLAR   LAVAGE 
The sputum and BAL in the asthma patient have the following features: 
1. Cork screw shaped twists of condensed mucus ( Curschmann’s spirals) 
2. Clusters of surface airway epithelial cells. ( Creola bodies) 
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3. Eosinophils, metachromatic cells admixed with granule membrane 
lysophospholipase (Charcot – Leyden crystals)  
4. Epithelial cells sloughing, eosinophilic cationic protein, major basic 
protein.30 
 
AIRWAY PLUGGING  
 These are the result of mucus production by enlarged sub mucosal glands, 
mixed with inflammatory exudate, arranged in concentric lamellae.  These plugs 
block the lumen of airways in asthmatics. 
 
HISTOLOGICAL APPEARANCE 
 The mucosa of the airway in asthmatics show loss of integrity of 
epithelial surface, thickening of the basement membrane, mucosal infiltration 
with eosinophils, lymphocytes, smooth muscle hypertrophy.  There is also 
dilatation of bronchial mucosal blood vessels as well as angiogenesis.32 
 
 
Figure 6: Mucosa Of The Airway In Asthmatics 
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DIAGNOSIS 
HISTORY 
• Abrupt onset of symptoms 
• Variable in time and intensity 
• More at Night 
• Exaggerated by laughing, walking, allergens and low temperature 
• Exacerbate with respiratory infection 
• Changes in symptoms according to seasons 
• Family history asthma, allergy or atopy. 
 
SYMPTOMS 
The symptoms vary with time, intensity or disappear during symptom free 
intervals. 
• Wheeze 
• Chest tightness 
• Cough 
• Shortness of breath. 
 
FINDINGS ON PHYSICAL EXAMINATIONS 
• Breath sounds with prolonged expiration 
• Increased respiratory rate 
• Orthopnoea 
• Chest constriction 
• Polyphonic, high pitched wheeze, maybe inspiratory, expiratory or both. 
• In near fatal asthma, chest maybe silent 
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PULMONARY FUNCTION TEST 
1. SPIROMETRY 
 Spirometry is the measure of airflow and lung volumes during a forced 
expiratory manoeuvre from full inspiration. It is fundamental to the diagnosis 
and assessment of airway disease. The measurements made during spirometry 
are referred as `dynamic lung volumes’.  Spirometry provides three basic 
measurements. 
• Forced vital capacity 
• The forced expiratory volume in one second. 
• The ratio of FEV1/FVC. 
 
 Airway obstruction is established by a decrease in FEV, out of proportion 
to the decrease in vital capacity (VC).This imparts a reduction in FEV1/FVC 
ratio. The maximum mid expiratory flow (MMEF) represents the airflow in the 
medium and small airways (FEF 25-75%).It may indicate mild airway disease. 
 
 Confirmation of asthma in spirometry is by establishing 
bronchoconstriction as evidenced by FEV1/FVC<70% and an improvement of 
>15% or 200ml in FEV1, 15 min after giving short acting beta 2 agonist by 
inhalation.1, 40 
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PEAK EXPIRATORY FLOW 
 This can be measured during spirometry or independently using a peak 
flow meter. Peak flow meter indicates only the greatest expiratory flow. It is 
used for monitoring the treatment. The two largest repeated measurements with 
variation within 5% is acceptable. The PEFR measurements are evaluated by 
comparing with the same person’s best value, which is obtained during symptom 
free period. It has diurnal variation, being lowest in early morning. 
 
 The meters used by the patients at home have a zonal system with colour 
code for better interpretation. The PEFR of 80%-100% of the patient’s best 
value is indicated by green zone, 60%-80% by yellow zone, below 60% by red 
zone. Red zone warns immediate medical care.1 
 
LUNG VOLUMES 
 The changes occuring in lung volumes and capacities of the asthmatic 
patients are: 
1. Increased total lung volume 
2. Increased functional residual capacity 
 
BRONCHIAL PROVOCATION TEST: 
 This is used in adult patients who do not have limitation of airflow at the 
time of assessment. Airway hyper responsiveness in such patients is 
demonstrated by bronchial provocation with methacholine or histamine. A 
decrease in FEV1 ≥ 20% from baseline is considered as bronchial asthma. The 
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specificity of this test is low as it can give false positive results in patients with 
other diseases.40,42 
 
TYPICAL CHARACTERISTICS OF ASTHMA, COPD, AND ACOS 
(Asthma-COPD overlap syndrome) 1 
FEATURE ASTHMA COPD ACOS 
Age Any age                                            Early onset Rare < 35 yrs. 
Usually >40 year 
History of symptoms      
present at early age. 
 
Occurrence 
 
Variable 
Aggravating 
factors present 
Persistent 
symptoms   
Prolonged course 
Persistent symptoms                                                 
Prominent variability 
Lung 
function 
Variable airflow 
limitation, 
normal between 
symptoms 
Post bronchodilator 
FEV1/FVC < 0.7 Not fully reversible 
History 
Mostly family/ 
personal history 
of allergy/ 
asthma present 
History of 
exposure to 
noxious substance 
present 
History of asthma, 
exposure to noxious 
substance present 
Disease 
course 
Improve after 
treatment Progressive 
Improve after treatment, 
Progressive 
Chest X ray Usually within 
normal limits 
Changes suggestive 
of COPD present Same as COPD 
Airway 
pathology 
Presence of 
eosinophils 
and/or 
neutrophils 
Neutrophils in 
sputum, may have 
systemic 
inflammation 
Eosinophils and/or 
neutrophils in sputum 
 
Table 1: Characteristics Of Asthma, COPD And ACOS 
 
  
 
       FLOW-CHART FOR DIAGNOSIS OF BRONCHIAL ASTHMA
Figure:7 Flow
 
Patient with following symptoms either intermittent or persistant:
Elaborate history and thorough physical examination
Do spirometry/PEFR with reversibility test
FEV1≤80% of 
normal 
FEV1/VC≥70%
Suspect 
restrictive lung 
disease
Specific 
diagnostic 
testing
28 
 
-chart For Diagnosis of Bronchial A
 
1. Shortness of breath
2. Wheeze
3. Chest tightness
4. Cough
FEV1≥15%
Reversibility test
FEV1/VC<70% FEV1>80%of 
FEV1/VC
Bronchial 
hyperactivity and 
or peak flow 
variability
ASTHMA
42, 1
   
 
 
sthma 
normal 
≥70%
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CLASSIFICATION OF BRONCHIAL ASTHMA: 
1. ACCORDING TO THE LEVEL OF CONTROL42: 
SYMPTOMS 
AND SIGNS CONTROLLED 
PARTLY 
CONTROLLED UNCONTROLLED 
1.Daytime 
symptoms 
Nil or 
<2times/week ≥2times/week  
2.Activity 
limitation Nil Present 
3/more feature of 
partly controlled 
asthma 
3.Night waking 
due to asthma Nil Present 
3/more feature of 
partly controlled 
asthma 
4.Need for 
reliever 
medication 
Nil or 
<2times/week >2times/week  
5.Lung 
function 
PEF/FEV1 
Normal <80% predicted  
 
Table 2: Classification Of Bronchial Asthma 
 
2. IN ACCORDANCE WITH THE CLINICAL SEVERITY: 
(i). MILD ASTHMA     
 It is a well controlled asthma. It is treated with reliever medications or 
with low intensity controller medications as and when needed basis. The 
spirometry value of FEV1 is 60-80% of the predicted value. 
 
(ii) MODERATE ASTHMA 
 These patients also have well controlled symptoms but with low dose 
ICS/LABA. Moderate asthma correlates with the FEV1 of 40-60% of the 
predicted value. 
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(iii) SEVERE ASTHMA 
 Patients in this state, need high dose ICS/LABA to control the symptoms. 
It may remain uncontrolled even with this treatment. 
 
 In severe obstruction, the FEV1 value will be <40% of the predicted.40 
 
PRIMARY PREVENTION 
 Focus is laid on environmental triggers of asthma and its evidence. 
Priority to the reduction of exposure to occupational allergens helps in 
decreasing the incidence of asthma. The main of aim primary prevention is to 
protect the children from developing asthma. Few ways of   achieving this are 
avoidance of maternal smoking, promoting breast feeding and avoidance of 
allergens. For obese individuals weight loss is advised.41, 43 
 
ASTHMA - INFORMATION EDUCATION AND COMMUNICATION: 
 Effective asthma management depends on the patients and parents of 
paediatric patients’ knowledge and understanding of asthma. Health education 
should begin as early as the diagnosis is made and should continue at each visit 
to hospital. 
 
 Healthcare providers should impart knowledge about the multifactorial 
nature of the disease and teach the patients about the practical skills needed for 
its better management. 
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Importance has to be laid on the identification and avoidance of precipitating 
factors, adherence to treatment and understanding the difference between 
reliever and preventer drugs. 
 
 Special attention is given for the technique of using inhaler devices and 
peak flow meter. They are educated to appreciate the day to day variability in 
peak expiratory flow rate and its role in recognising the influence of 
precipitating factors, their effect on disease process and in monitoring the 
treatment. 
 
 The healthcare provider should have good communication skill. Then 
only the needed information can reach to the patient. For this they should have a 
friendly nature and allow the patients to express their problems, beliefs and 
concerns. Besides being attentive, they have to impart appropriate information, 
reassure and encourage the patients. Hence good communication has a great 
impact on health literacy. The information should be in simple words with 
illustrations, pictures, drawing, etc. Patient’s understanding can be confirmed by 
asking to repeat the important points. It means the patients clear understanding 
and the freedom to put forward their doubt.1,42 
 
AVOIDANCE OF PROVOKING FACTORS: 
 Indoor allergens like house dust mite prevalence can be reduced by 
frequent dusting, vacuum cleaning and covering the carpet and mattresses etc. 
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 Exposure to pet allergens should be avoided. Cigarette smoking both 
active and passive has to be abstained. Occupations and hobbies that provoke 
asthma have to be evaded as well. Ingested food additives, food allergens which 
trigger asthma have also to be refrained. Furthermore, medications which cause 
bronchoconstriction like beta blockers, aspirin etc. are to be avoided.1, 42                           
 
PHARMACOTHERAPY OF BRONCHIAL ASTHMA 
Various means of bronchial asthma treatment are: 
1. To decrease airway inflammation and hyper responsiveness. 
2. To prevent the bronchoconstriction effect of vagal nerve 
• Anti cholinergics 
3. Dilatation of airway smooth muscles- 
• Sympathomimetics 
• Methylxanthines 
4. Blocking the release of anti-inflammatory mediators- 
• Mast cell stabilizers 
5. Antagonising the effect of already released mediators of inflammation 
• Leukotriene antagonists 
• Antihistamines 
• PAF antagonists 
6. Blocking the circulating IgE- 
• Omalizumab 
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ANTIASTHMATIC DRUG CLASSIFICATION 
1. BRONCHODILATORS 
• Agonists of beta2 adrenergic receptors 
• Anticholinergics 
• Methylxanthines 
2.LEUKOTRIENE RECEPTOR ANTAGONISTS    
• Montelukast 
• Zafirlukast 
• Lipoxygenase inhibitor-zileuton 
3. PREVENT DEGRANULATION OF MAST CELLS 
• Sodium chromoglycate 
• Ketotifen  
4. CORTICOSTEROIDS 
• Inhaled route: beclomethasone, dipropionate, budesonide, 
fluticasone,  Propionate, flunisolide, ciclesonide 
• Systemic route: Hydrocortisone, Prednisolone etc. (42)  
 
The use of above mentioned drugs fall under two categories: 
 The ‘relievers’ and the ‘controllers’. The relievers are bronchodilator 
drugs used on need basis. Controllers are anti-inflammatory drugs taken in daily 
basis for prolonged period to keep symptoms of asthma under control.1, 42 
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BETA 2 ADRENORECEPTOR AGONISTS:  
 These act on the beta2 receptors on bronchial smooth muscle resulting in 
bronchodilation. Beta2 agonists stimulate the G protein coupled receptors that 
result in activation of adenylcyclase and finally increase cAMP which cause 
smooth muscle relaxation. cAMP also decreases mediator release from mast 
cells. These agents inhibit microvascular leakage and increase mucociliary 
transport by increasing ciliary activity. 44 
 
 Selective beta2 agonists are preferred agents for bronchial asthma. By 
inhalation route they are the fastest acting drug. 
 
 Salbutamol, pirbuterol and terbutaline are faster acting drugs by 
inhalational route. So they are used for aborting an attack of acute asthma. 
Owing to their short duration of action, they are not suitable for prophylaxis. 
 
 Salmeterol, formoterol, carmoterol, indacterol are long acting beta2 
agonists. They are useful for prophylaxis of bronchial asthma. 
 
Adverse reactions: 
 Prolonged use may lead to down regulation of beta receptors contributing 
to tolerance. Tremors, palpitation, decrease serum potassium concentration, 
restlessness are other side effects.6 
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METHYLXANTHINES: 
 This group includes caffeine, theophylline and theobromine. 
Methylxanthines act by blocking the adenosine receptor, increase cAMP, 
inhibition of phosphodiesterase enzyme. At higher doses, these drugs release 
calcium from sarcoplasmic reticulum in skeletal and cardiac muscles. 
 
 When given orally they have rapid absorption. Metabolism is via cyp450 
isoenzymes in liver. This paves way for a multitude of drug interactions.6 
 
Side effects: 
 As these drugs are CNS stimulant at toxic doses they result in tremors, 
delirium and convulsions. Vomiting occurs due to gastric irritation and CTZ 
stimulation. More over theophylline has a narrow therapeutic index which plays 
a central role in causing toxic symptoms. 6 
 
ANTICHOLINERGICS: 
 Cholinergic blockers are effective only if bronchoconstriction is due to 
cholinergic activity. These drugs cause mainly dilatation of large airways. These 
are less efficacious and slower acting bronchodilators than the 
sympathomimetics. 6These drugs are more effective for COPD than bronchial 
asthma. 
 
 Ipratropium and tiotropium act as competitive antagonists of Ach 
receptors on bronchial   smooth muscle. They act through M3 receptors which 
are G Protein Coupled receptors.44These drugs are inhalational agents. The 
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duration of action of Ipratropium is 4-6hrs while that of tiotropium is 24hrs.Both 
are ionic drugs that are poorly absorbed.6, 29 
 
Side effects: 
 Dryness of mouth, nervousness, pharyngitis, headache, palpitation. 
 
CORTICOSTEROIDS: 
 These drugs have potent anti-inflammatory and also decrease bronchial 
hyperactivity and mucosal edema. Anti-inflammatory action is due to decreased 
recruitment of inflammatory cells as well as decreased production of PG and LT. 
They block the mediators generated by arachidonic acid pathway. 
 
 Glucocorticoid bind to cytoplasmic receptors and the complex is 
transferred to the nucleus. These GR-drug complex binds to the nuclear response 
element present in the DNA. This results in up regulation transcription of anti-
inflammatory factors. 45                    
 
 The primary indication of inhaled steroids is to decrease the inflammatory 
process. These drugs are used as maintenance therapy of chronic persistent 
asthma. Beclomethasone, dipropionate, Triamcinolone, Fluticasone, Budesonide, 
Mometasone are some of the agents used in inhalational route. Inhaled steroids 
are combined with long acting beta2 agonists and used as controller medication 
in bronchial asthma. 48 
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Side effects: 
 The systemic therapy with glucocorticoids cause abnormalities in 
metabolism of carbohydrates, lipids, cushingoid features with salt and water 
retention, alteration in mood, osteoporosis, hypertension, cataract, 
immunosuppression  etc. 46 Local effects like oropharyngeal candidiasis, 
dysphonia, pharyngitis are seen with inhaled steroid use.47 
 
CROMOLYN LIKE DRUGS: 
 Sodium chromoglycate and nedocromil are the most common 
nonsteroidal antiasthmatic drugs used. They prevent degranulation of mast cells 
in response to allergic-non allergic stimuli .They are indicated only for 
prophylaxis of asthma. When used as inhalational agents they prevent 
bronchospasm and the cascade of further mediator release. Ketotifen has anti 
histaminic action apart from mast cell stabilizing   property and is specially 
indicated for patients with multiple disorders like atopic dermatitis, perennial 
rhinitis, conjunctivitis etc. chromoglycan and nedocromil are often used in 
pediatric population as alternatives to inhale corticosteroids because of their 
safety profiles.45 
 
Adverse reactions: 
 Local reactions like pharyngeal irritation, cough, reflex bronchospasm are 
observed .Headache, arthralgia, nasal congestion are rarely reported. 
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LIPOOXYGENASE INHIBITOR: 
 Zileuton inhibits the synthesis of LTB4, LTC4, LTD4 from arachidonic 
acid. This results in blocking of chemotaxis and bronchoconstriction. This drug 
has short duration of action. It is used as controller in the management of 
bronchial asthma. 50 
 
Adverse reaction: 
 Nonspecific pain, headache, acid peptic disorder, elevated liver enzymes 
and hepatotoxicity.51 
 
LEUKOTRIENE RECEPTOR ANTAGONIST: 
 Montelukast and zafirlukast inhibit the bronchoconstricting   action of 
LTs at cys LT1 receptor.51They are selective antagonists of leukotriene receptors 
LTD4 and LTE4. By this action they inhibit bronchoconstriction, mucus 
secretion, vascular permeability and plasma exudation into the air way. 
Antileukotrienes are indicated in prevention of exercise, cold air, allergens and 
aspirin induced asthma.51 
 
Adverse reactions: 
 Headache, nausea, abdominal pain, occasional elevation of liver enzymes 
are reported.  Few cases of Churg Strauss syndrome is associated with their 
use.51 
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MONOCLONAL ANTIBODY-OMALIZUMAB: 
 Omalizumab is a monoclonal antibody against IgE. It blocks the reaction 
between IgE and mast cell / basophils .This inhibits the release of inflammatory 
mediators. It is indicated to prevent the attack of bronchial asthma in patients not 
responding to combination of long acting beta 2 agonist and a high dose of 
inhalational steroid. It is administered by subcutaneous route. 
 
Adverse reactions: 
 Injection site reactions, viral, respiratory tract infections, headache, 
sinusitis and pharyngitis. 52 
 
MANAGEMENT OF ASTHMA 
BASED ON PATIENT’S CONTROL OF ASTHMA SYMPTOMS: 
 
Figure 8: Control based asthma management cycle 
 
 Symptoms control serves as a tool for planning asthma management. The 
exceptions are severe asthmatics whose symptoms do not correlate with 
Assess
Adjust 
treatment
review 
response
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responses or exacerbations .This approach of asthma management takes into 
account not only symptom control but also the future risk reduction. 42 
 
STEPPING DOWN AND STEPPING UP ASTHMA TREATMENT 
Steps in asthma management 
STEP1: Using reliever medication as and when needed basis. 
STEP2: Continuous use of low dose controller medication added to step 1. 
STEP3: Use of one or two controller medications along with step 1. 
STEP4: Use two or more controller medications along with step 1. 
STEP5: Tertiary care and / or add on medications. 
 
 Asthma patients should be followed up regularly and assessed for asthma 
control, adherence to medications, inhaler techniques etc. 
 
 If they do not respond to treatment then these step up treatment has to be 
given. If the asthma symptoms are well controlled and the lung function is stable 
for 3 or more months, then stepping down treatment may be considered.1, 42 
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Figure 9: Step wise approach to control asthma symptoms and  
minimize future risk 
 
                            DRUGS USED IN PRESENT STUDY 
METHYLXANTHINE GROUP OF DRUGS: 
 Methylxanthine is present in beverages like tea, coffee, cocoa. The CNS 
stimulant effect of these are attributed to methylxanthines. The major chemicals 
present are theophylline, theobromine and caffeine. 
 
CHEMICAL STRUCTURE: 
Theophylline is 1,3-dimethylxanthine 
Theobromine is 3, 7-dimethylxanthine 
  
 
Caffeine is 1, 3, 7-trimethylxanthine
1-Methylxanthine                        
Figure 10: Structure Of Methylxanthine And Theophylline
 
MOLECULAR BASIS
1. Phosphodiesterase inhibition
2. Antagonism at adenosine A
3. Inhibition of nuclear factor K
4. Inhibition of phospho
5. Increased interleukin 10 secretion
6. Enhanced apoptosis of inflammatory cells
7. Decreased expression of ADP
death. 
8. Increased histone deacetylase activity
 
PDE INHIBITION: 
 Theophylline is a nonselective inhibitor of phosphodiesterase. It acts on 
cyclic nucleotides, increases intracellular ade
cyclic 3’5’ guanosine monophosphate (GMP) levels. Higher expression of 
42 
 
    
Theophylline
 
 OF THEOPHYLLINE ACTION: 
. 
, A2A, A2B receptors. 
-β. 
-inositol-3 kinase δ. 
. 
.  
-ribose polymerase 1 which inhibits cell 
. 
nosine monophosphate (AMP)  and 
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isoenzymes of PDE are encountered in bronchial asthma patients owing to its 
chronic inflammatory process or as a treatment outcome.54 
 
ADENOSINE ANTAGONIST: 
 Theophylline inhibits A1 and A2 subtypes of adenosine receptors and is 
less potent against A3 receptors. It antagonises the bronchoconstricting effects of 
adenosine. 55 
 
INTERLEUKIN 10 RELEASE: 
 Interleukin 10 plays major role in anti-inflammatory actions. IL-10 
concentrations are low in diseased states like asthma and COPD. IL-10 secretion 
enhanced by theophylline .56 
 
EFFECTS OF GENE TRANSCRIPTION: 
 It decreases the expression of genes responsible for inflammation in 
asthma. This effect is mediated by blocking the translocation of nuclear factor 
KB(NF-KB)which is a proinflammatory transcription factor into the nucleus.57 
 
EFFECTS ON KINASES: 
 Theophylline has direct inhibitory action on phosphoinositol 3 kinase, 
particularly the subtype P13K (P110) δ. This enzyme takes part in oxidative 
stress response. This property contributes to the theophylline’s reversal action of 
corticosteroid resistance. This plays a major role in the management of severe 
asthma and COPD. 58 
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EFFECTS ON APOPTOSIS: 
 Theophylline has the property of reducing apoptosis by virtue of its action 
on Bcl-2, an antiapoptic protein. This contributes to the inhibition of apoptosis in 
neutrophils.59 
 
HISTONE DEACETYLASE ACTIVATION: 
 Acetylated and deacetylated state of histone determines the inflammatory 
gene expression. Bronchial asthma patients have increased expression of 
inflammatory genes as a result of histone acetylation and transcription. 
 
 This phenomenon is prevented by histone deacetylases (HDAC) which 
acts on the promoter site present in the nucleus. Corticosteroids inhibit the 
inflammatory process by the activation of histone deacetylase, thus suppressing 
the expression of inflammatory genes. (61) This process is defective in COPD 
patients causing reduced expression of HDAC2 and contributing to steroid 
resistance in COPD. This defect is also encountered in severe asthmatic patients 
who have the habit of smoking. 62 
 
Figure 11: Reversal of steroid resistance - activation of HDAC by 
theophylline. (54) 
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 Theophylline enhances the action of HDAC5 and improve the anti-
inflammatory effect of corticosteroids. It also serves to reduce the resistance to 
steroids in COPD patients. 63 This is encountered at low blood levels and during 
oxidative stress and stress due to nitrogen and its metabolites. In bronchial 
asthma theophylline decreases the formation of peroxy nitrite and increases the 
function of HDAC2. 64 
 
IMMUNOMODULATORY EFFECT: 
 Theophylline improves the function of CD8+ T-lymphocytes and 
decreases the chronic inflammation of the airways .It also reduces IL-4 and IL-5 
levels in asthmatics. 65 
 
EXTRA PULMONARY EFFECTS OF METHYLXANTHINES: 
 Aminophylline enhances the contraction of diaphragm, thus reducing 
diaphragmatic fatigue. 66 
 
 
Figure 12:  Cellular Effects Of Theophylline54 
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CELLULAR EFFECT: 
 At cellular level theophylline has multiple actions which pave way in the 
improvement of bronchial asthma.  
 
PHARMACODYNAMICS OF METHYLXANTHINES: 
 The effects of methylxanthine are exerted in various organ systems of our 
body like CNS, kidney, cardiac, skeletal muscles and smooth muscles. Various 
methylxanthines prefer different tissues for their action .Theophylline has 
preference for smooth muscles while caffeine acts on CNS. 
 
EFFECTS ON CENTRAL NERVOUS SYSTEM: 
 These drugs cause cortical stimulation and improve the alertness while 
decreasing fatigue. They cause nervousness and tremor in few individuals. 
Higher doses lead to stimulation of medulla, convulsion and death.67 
 
CARDIOVASCULAR EFFECTS: 
 Methylxanthines block the presynaptic adenosine receptors enhancing the 
concentration of catecholamine in synaptic cleft. This results in positive 
chronotropic as well as ionotropic effects on heart. Methylxanthine renders the 
blood less viscous leading to increased blood flow which helps in treating 
intermittent claudication .Pentoxifylline is used for this purpose.67 
 
EFFECTS ON GI TRACT: 
 Methylxanthine promotes the secretion of gastric acid and other digestive 
juices. 
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EFFECTS ON KIDNEY: 
 Methyxanthine cause mild diuresis as a result of enhanced glomerular 
filtration as well as decreased tubular reabsorption. But this is a meagre response 
which could not be utilized therapeutically. 67 
 
EFFECTS ON SMOOTH MUSCLE: 
 This relaxation effect is utilised for management of bronchial asthma. No 
tolerance is encountered for this action. 
 
EFFECTS ON SKELETAL MUSCLE: 
 Methylxanthine enhance the magnitude of skeletal muscle contraction. It 
improves the function of diaphragm and leads to better response to hypoxia and 
decrease dyspnea. 
 
                                             CLINICAL USES 
1. ACUTE SEVERE ASTHMA: 
 Aminophylline was used earlier as an intravenous agent for acute 
management of severe asthma. Due to its enhanced spectrum of adverse effects, 
nebulised beta2 agonists are now used in this situation. Aminophylline use is 
now restricted to non responding individuals.68 
 
2. CHRONIC ASTHMA: 
 In patients who are already on inhaled steroids for asthma control, 
theophylline demonstrates better level of control than beta2 agonists.69 
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 As sustained release formulations, methylxanthines are useful in the 
management of nocturnal asthma. They provide overnight control symptoms.70 
 
3. ADD ON THERAPY: 
 Studies suggest that including low dose theophylline as add on therapy 
for patients not responding to inhaled steroids provide better relief than doubling 
the inhaled steroid dose.71, 72 
 
4. COPD: 
 Theophylline provides increased exercise tolerance, reduces air trapping, 
stress due to nitrogen in COPD patients.73 
 
ADVERSE EFFECTS: 
 Increased incidence of adverse events limit the use of theophylline. The 
adverse effects mediated by adenosine receptor inhibition like central nervous 
system stimulation, gastric acid production, diuretic effect, cardiovascular 
effects like arrhythmias may be minimised by the use of drugs that inhibit 
phosphodiesterase or doxofylline.75 
 
 The unwanted effects mediated through PDE inhibition are nausea, 
vomiting, palpitations, arrhythmias, headaches 76. 
 
 The adverse effects of theophylline correlates with its serum level. It 
occurs most commonly at the concentrations more than 20mg/l .Few individuals 
encounter these reactions at lower concentrations itself. Apart from the above 
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effects, very high concentration may lead to convulsions &  cardiac 
arrhythmias.6 
 
CLEARANCE OF METHYLXANTHINES: 
The following situations increase the clearance of methylxanthines: 
1. Enzyme induction (CYP1A2) by other drugs used simultaneously like 
rifampicin, barbiturates, ethanol and others. 
2. Smoking induces the enzyme CYP1A2 causing increased clearance. 
3. A diet rich in protein and low in carbohydrates. 
4. Barbecued meat. 
 
The conditions which decrease the clearance of methylxanthine and increase the 
serum concentration are: 
1. Inhibition of cytochrome P450 isoenzyme by other drugs like cimetidine, 
erythromycin, ciprofloxacin, allopurinol, zileuton, zafirlukast. 
2. Congestive cardiac failure 
3. Hepatic disease 
4. Pneumonia 
5. Viral infection 
6. Carbohydrate rich diet 
7. Geriatric population  
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DOXOFYLLINE 
 
Figure 13: Structure Of Doxofylline 
 
7(1,3 dioxolone-2methyl)theophylline is doxofylline. It differs from theophylline 
by the presence of dioxolane group in position 7. 
 
PHARMACOKINETICS: 
 Oral bioavailability is 62.6% peak serum concentration is attained, at 
about 1.19hr.It takes 6hrs to reach the steady state .AUC of doxofylline is 
69.5microgram/ml .It is 48% protein bound with distribution half-life of 
0.19hr.Volume of distribution is 1 l/kg. 
 
 About 90% of doxofylline is metabolized in liver into inactive metabolite 
hydroxyethyl theophylline. It is excreted by kidney. Its elimination half-life is 7-
10 hours. Dose-400mg o.d / b.d oral. 
 
  
  
 
       
Figure 14
 
PHARMACOKINETICS:
 Theophylline is rapidly and completely absorbed when given orally.
Maximal plasma concentration is attained within 2hrs.
of its absorption. Rate of absorption is decreased 
position. 
 
 Theophylline is uniformly distributed throughout the body,
placenta and secreted in breast milk.
drug is excreted in urine.
 
 The elimination kinetics of theophylline varies according to its plasma 
concentration. It follows first order kinetics within the therapeutic range while it 
changes to the zero order kinetics at higher concentration.
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DERIPHYLLINE             
: Structure Of Deriphylline 
 
 Food slows down the rate 
by sleep and recumbent 
 Metabolism takes place in liver.15% of 
 Average half-life of theophylline is about 20
6 
 
 
 
 crosses the 
-36hrs. 
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CLINICAL TRIALS ON METHYL XANTHINES 
 
 The study done by Goldstein M F, et al. is a double blind randomized 
place controlled multicentric clinical trial.   This study states that the use of 
doxofylline resulted in a reduction frequency of asthmatic attacks and also 
significantly lowered the use of salbutamol in asthmatics for symptomatic relief. 
It also showed enhanced bronchodilatation which is indicated by elevated mean 
forced vital capacity and peak expiratory flow rate. Adverse reactions are 
encountered more in the theophylline group.77 
 
 In this study Cogo R, et al. proposed that there is less inflammatory 
change and modification in cell proliferation by the use of doxofylline in chronic 
obstructive bronchitis patients. He found out a marked decrease in bronchial 
inflammation and infiltration of neutrophils in the bronchoscopy specimens of 
patients who improved clinically.78 
 
 Bagnato GF evaluated the tolerability of doxofylline as maintenance 
therapy. This study throws light on the safety and better side effect profile   of 
doxofylline. 79 
 
 Lazzaronim, et al. conducted a study on duodenal ulcer patient comparing 
the effects of doxofylline and aminophylline in inducing gastro esophageal 
reflux. It revealed that less lower esophageal sphincter pressure and change in 
gastric   motility in the patients on doxofylline   therapy. He concluded that 
doxofylline is safer in asthmatic patients who suffer with peptic ulcer disease.80 
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 In his study on the effect of doxofylline and theophylline in sleep, Sacco 
et al. declared that theophylline caused insomnia, increased awakening at night, 
and less Rapid Eye Movement Sleep when compared with doxofylline.82 
 
PERSPECTIVE OF METHYL XANTHINES 
 Due to the widespread use of ICS, inhaled β2 agonists, the role of 
Methylxanthines in asthma is decreasing. But sustained release Theophylline has 
a prominent place in developing countries as an affordable antiasthmatic drug. 
Theophylline`s effect not only ends with  bronchodilatation but also has other 
significant effects in asthma  patients even at lower serum concentrations.6 
 
 Combined use of ICS and Theophylline has better effect in severe 
asthmatics and COPD patients. It is evident that we can add Theophylline 
instead of doubling the dose of ICS, it can reverse steroid resistance by acting on 
HDAC2   and helps in COPD patients. Hence Theophylline`s role in asthmatics is 
essential in developing countries like India. 6, 83 
 
NOVEL THERAPY FOR BRONCHIAL ASTHMA 
 SMART STRATEGY:  
 This is the usage of Single inhaler maintenance and Reliever Therapy. A 
combination of Budesonide and Formoterol is used as controller and preventer 
medication in bronchial asthma patients.84     
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INFLAMMATORY MEDIATOR ANTAGONISTS: 
 As asthma involves a cascade of mediators and various receptors, 
antagonists of single receptor or mediator will not be effective in bronchial 
asthma treatment. 6,85 
 
CRTH2 ANTAGONIST: 
 These are new class of drugs acting on DP2  receptors of prostaglandin. 
Crth2  is the chemotactic factor for TH2 cells. These drugs are in trial for usage in 
bronchial asthma and other allergic disorders.86 
 
ENDOTHELIN ANTAGONISTS: 
 These drugs are used for the treatment of pulmonary hypertension and 
they may be helpful in treating the structural changes occurring in asthma and 
COPD.6 
 
ANTIOXIDANTS: 
 Antioxidants like Vit. C, Vit E, N-acetyl cysteine reduce the oxidative 
stress which participates in steroid resistance in asthma and COPD.87 
 
CYTOKINE MODIFIERS: 
 Reslizumab is a monoclonal antibody against IL-5. Blocking IL-5 
interferes with eosinophilic survival and priming. This resulted in reduced 
sputum eosinophils and some improvement in symptoms. 
 
 Pitrakinra blocks the IL-4 receptor reducing the late response to allergic 
stimuli in bronchial asthma patients.89 
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 Lebrikizumab, a monoclonal anti body against IL-13, produces an 
increase in FEV, in some asthmatics.90` 
 
CHEMOKINE RECEPTOR ANTAGONISTS: 
 Mogamulizumab, antibody to CCR4 causes decreased TH2 production 
which is tried in asthmatics as well as  T Cell leukemia /  Lymphoma patients.92 
Navarixin, CXCRI / CXCR2 antagonist blocks neutrophils in sputum which is 
on trial for asthma.93 
 
NEW ANTI- INFLAMMATORY DRUGS: 
 Phosphodiesterase 4 inhibitors, Nfk- B inhibitors, MAP – Kinase 
inhibitors, mast cell inhibitors, Mucoregulators, Mucolytics PPAR γ agonists are 
all tried in asthma. 94,95, 96 ,97,98,99,100,101 
 
NOVEL CLASSES OF BRONCHODILATORS: 
 Ultra LABA like indacaterol, carmoterol, vilanterol, olodaterol which are 
used along with inhaled steroids, are used as once daily dosage in asthmatics.102 
 
NONSTEROIDAL SELECTIVE GLUCOCORTICOID RECEPTOR 
ACTIVATORS: 
 Nonsteroidal selective glucocorticoid receptor activators (mapracorat) 
also known as disassociated corticosteroids have differential action. The 
transactivation in disassociated from transrepression leading to better therapeutic 
effects and lesser side effects. 104 
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NON ANTIBIOTIC MACROLIDES: 
 These are new class of drug which do not have antibiotic effect but have 
anti-inflammatory effect by inhibiting NE Kb. These drugs also found to reverse 
the steroid resistance caused by oxidative stress. 105 
 
  
Materials  
and  
Methods 
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MATERIALS AND METHODS 
 
SOURCE OF DATA: 
 Patients diagnosed to have mild to moderate persistent bronchial asthma, 
attending the Thoracic medicine out- patient department of Chengalpattu 
Medical College Hospital. 
 
COLLABORATING DEPARTMENTS: 
 Department of Pharmacology, Pathology, Medicine, Radiology Thoracic 
Medicine, Chengalpattu Medical College. 
 
ETHICAL CLEARANCE: 
 Obtained on 11.06.2014   
 
METHODS OF DATA COLLECTION: 
Study Design  : Randomized prospective, open labeled comparative study 
Study Period :  1 year (Jul2014-Jun2015) 
Sample Design: Randomised sample 
Sample Size   : 186 
 
Inclusion Criteria:   
1. All adult patients (> 18 years of age) diagnosed with mild to 
moderate persistent bronchial asthma (may use concomitant 
medications as and when needed according to the severity) 
2. Willing for investigations  
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3. Agree to give informed written consent   
4. Willing for follow up visits 
 
Exclusion Criteria: 
1. Major respiratory illness other than asthma like chronic obstructive 
pulmonary disease or other relevant lung disease causing impairment in 
lung function. 
2. Patients with co-morbid conditions – Ischemic heart disease,    congestive 
cardiac failure, renal and hepatic dysfunction, neurological endocrinal 
haematological and other abnormalities..  
3. Pregnant and lactating women.  
4. History of known allergy/intolerance/hypersensitivity to study drugs.            
5. Patients on regular treatment with drugs that interact with 
methylxanthines 
6. Patients < 18 years of age 
7. Patients who do not give consent for the study. 
8. Discontinuation Criteria: 
9. Patients were permitted to discontinue from the study if they decided to 
do so. 
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ASSESMENT TOOLS 
 INFORMED CONSENT  
 Informed consent form which clearly sates the details of the study and has 
written consent in both English and regional language was used. The study was 
explained to the participants in their own language and written informed consent 
was got. 
 
 PREVIOUS HISTORY AND PHYSICAL EXAMINATION: 
 A detailed history along with thorough physical examination was done 
and the same is recorded in the case sheet. 
 
 ASSESSING THE COST OF TREATMENT: 
 Information required for calculating the cost of treatment like wages, 
accompanying person details, distance from the health facility and other relevant 
information are collected and recorded. 
 
 USE OF PARAMETERS: 
 Parameters like weight and height are taken. BMI is calculated by 
Quetelet`s index, 
 
                                    BMI= Weight in Kilograms 
                                                      Height in M2 
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 VITALS: 
 Pulse (beats/ min), Blood pressure (mm Hg)  
 
 This is measured using sphygmomanometer while the patient is in supine 
position. 
 
 Respiratory rate -  Measured by palpating the movement of chest wall 
of the patients. 
 
 ASSESSMENT OF EFFICACY: 
 (i) Spirometry:  
 It is a measure of airflow and lung volumes during a forced expiratory 
from full inspiration. It is fundamental to the diagnosis and assessment of airway 
disease. Parameters used as tools and FVC, FEV, FEV1/FVC and PEFR. 42 
 
(ii) Asthma Control Test: 
 This score helps to differentiate the levels of symptom control and used to 
evaluate the progress of the patient. The test has 5 questions, 4 of which pertain 
to symptoms and one is the patient`s self assessment of his level of asthma 
control. The maximum score is 25 and each question carries 5 points. A score of 
20-25 is taken as patient with well controlled asthma, 16-20 not well controlled, 
5- 15 are poorly controlled.42 
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(iii) Subjective rating of asthma control: 
 This scale consists scores in percentage. 0% indicates no control and 
100% means very well controlled asthma. The subjective rating is done by the 
patient considering his/her symptom control since last visit. 
 
 ASSESSMENT OF SAFETY: 
 Safety is assessed by adverse drug reactions which are reported by the 
patients, or enquired by the investigators, or from the observations of clinical 
examinations and laboratory reports. 
 
 ASSESSMENT OF COST EFFECTIVENESS: 
Cost: By calculating the direct and indirect costs119. 
Health Outcome: By the level of symptom – relief and free from side effects119. 
 
 PATIENT`S REVIEW SCHEDULE: 
(i) First Visit: The following were done in day I. 
• The entire study is explained to the patients including the purpose, 
procedure health benefits and written informed consent was obtained 
from each. 
• Patients were recruited according to the protocol. 
• Patient`s living place, means of transport medical history, concomitant 
medical history and other relevant information necessary for assessing 
cost were taken. 
• A detailed physical examination was done. 
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• Baseline investigations for asthma and lab parameters were performed 
for all patients recruited for the study. 
• Treatment given according to the group the patients belong. 
• All were advised to come for regular follow up and assessment in 4 
weekly interval was carried out for a period of 12 weeks.  
 
 Follow up visit: 
• Done at 4th, 8th and 12th weeks. 
• The patients were assessed for symptom control and clinical 
improvement using spirometry, asthma control test, and subjective 
rating of asthma control for subsequent period of visits.  
• Information about adverse reactions - voluntarily reported, observed 
and enquired were all collected. 
• Health education regarding asthma control was given to the patients in 
order to sustain their compliance. 
 
 At their visit on the 12th week, all laboratory parameters assessed at the 
baseline were again repeated. 
 
 ANALYSIS: 
 The data collected were analyzed using Student t test (two tailed, 
independent) to find the significance of study parameters on continuous scale 
between two groups (Inter group analysis) on metric parameters. Chi-square/ 
Fisher Exact test was used to find the significance of study parameters on 
categorical scale between two or more groups. 
 Results 
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RESULTS 
 
 186 patients were initially recruited for the study. Out of this, 26 patients 
were excluded from the analysis due to the following reasons: 21 patients were 
lost to follow up and 6 patients discontinued from the study 160 patients were 
analyzed for the study. 
 
GENDER AND AGE DISTRIBUTION 
 Among the 160 patients participated in the study, 38.8% in doxofylline 
group and 34% in deriphylline group were females and the rest were males. 
 
Sex Doxofylline group Deriphylline group Total Chisq p value 
F 31 34 65 0.233 0.6 
M 49 46 95 
  
Total 80 80 160 
  
 
Table 3: Gender distribution 
 
 
 
 
 
Figure 15: Gender Distribution 
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Doxofylline group Deriphylline group 
Age 45.31±7.5 44.08±9.6 
BMI 21.386±3.04 21.688±3.3 
FAMILY HISTORY 
NIL 60 47 
ALLERGY 1 10 
BRONCHIAL ASTHMA 19 23 
DURATION 6.97±3.57 7.46± 4.63 
AGGRAVATING FACTOR 
NIL 20 18 
% 25% 22.50% 
Dust 36 30 
% 60% 48.39% 
Air pollution 8 11 
% 13% 17.74% 
cold weather 18 21 
% 30.00% 33.87% 
 
Table 4: Comparison of Age, BMI, Family history, Aggravating Factor 
 
AGE:   
 Mean age of the patients in doxofylline group was 45.31±7.5 and those in 
deriphylline group was 44.08±9.6. 
 
BODY MASS INDEX:  
 The mean BMI of the patients participated in doxofylline group was 
21.30 while that of deriphylline group was 21.69 
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DURATION OF ILLNESS:  
 The patients recruited for doxofylline group had bronchial asthma for the 
mean duration of 6.97±3.57 years and the deriphylline group patients had the 
illness for a mean duration of 7.46±4.63 years. 
 
AGGRAVATING FACTORS:  
 75% of the patients on doxofylline and 77.5% of patients on deriphylline 
had one or the other aggravating factors. In majority of patients, environmental 
dust is a major cause in aggravating asthma (60% in doxofylline group and 
48.39% in deriphylline group). The contribution of other factors are as shown in 
the table. 
 
FAMILY HISTORY:  
 No family history was present in 60 patients of doxofylline group and 10 
patients in deriphylline group. History of bronchial asthma was present in 19 of 
doxofylline and 23 patients of deriphylline group. 10 persons in deriphylline 
group had family history of allergy. 
 
  
  
 
ESTIMATION AND COMPARISON OF 
Asthma 
 Doxofylline
Baseline 
I visit 
II visit 
III visit 
Table 5:
Figure 16
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Deriphylline 
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EFFICACY: 
Control Test questionnaire score 
 Deriphylline 
16.05±0.87 17.21±1.41 
17.88±1.24 18.14±1.38 
20.19±1.33 19.5±1.4 
24.42±1.12 20.69±1.08 
 
 Asthma Control Test questionnaire score
 
: Asthma Control Test questionnaire score
Baseline III visit 
16.05±0.87 24.42±1.12 
17.21±1.41 20.69±1.08 
 
: ACT Score - Improvement from baseline
17.88
20.19
18.14
19.5
act1 act2
ACT Score
DOXOFYLLINE DERIPHYLLINE
*
*
P < 0.005
P value 
0.209 
0.00 
0.002 
0.003 
 
 
 
P value 
0.002 
0.001 
 
24.42
20.69
act3
*
  
 
 The level of control of the disease as 
questionnaire revealed that there 
both groups compared with baseline
doxofylline group and
 
Subj
 
Baseline 
I visit 
II visit 
III visit 
Table 7:
 Figure 17
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assessed by asthma control test 
was statistically significant improvement in 
 and a significant differen
 the deriphylline group throughout the study.
ective rating of asthma control 
Doxofylline Deriphylline 
48.62±10.6 57.56±7.83 
62.32±7.29 62±8.0 
74.56±8.16 68.44±6.82 
84.94±4.87 74.06±6.01 
 
 Subjective rating of asthma control
 
 :  Subjective Rating Of Asthma Control
 
I visit II visit III visit
Doxofylline Deriphylline
*
* 
*p<0.005
ce between the 
 
P value 
0.789 
0.00 
0.00 
0.00 
 
 
 
* 
  
 
 
Doxofylline 
Deriphylline 
 
Table 8: Subjective Rating Of Asthma Control
 The results of subjective rating of asthma control showed significant 
increase in both groups compared with the baseline and subsequent visits. 
Significant improvement is encountere
the deriphylline group in all visits.
 
Comparison of forced vital capacity of the two groups of patients 
 
Baseline 
I visit 
II visit 
III visit 
Table 9: Comparison Of Forced Vital Capacity
Figure 18
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Baseline III visit 
48.62±10.6 84.94±4.87 
57.56±7.83 74.06±6.01 
Improvement From Baseline 
 
d in the doxofylline group compared with 
 
Doxofylline Deriphylline 
60.53± 3.72 61.23± 8.67 
68.32± 2.62 81.9± 7.97 
76.58± 2.57 77.4± 5.27 
81.48±2.06 89.95± 4.87 
 
: Comparison Of Forced Vital Capacity
Visit I Visit II Visit III
68.32
76.58
81.4881.9
77.4
89.95
P value 
0.0001 
0.0001 
-  
 
P value 
0.51 
0.13 
0.21 
0.39 
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 Baseline III visit P value 
Doxofylline 60.53±3.72 81.84±2.06 0.0001 
Deriphylline 61.23±8.64 89.95±4.87 0.0001 
 
Table 10: Comparison Of Forced Vital Capacity-  
Improvement From baseline 
 
 The results of lung function tests using spirometric parameters displayed 
a significant increase in the percentage predicted forced vital capacity in both the 
study groups compared to the baseline in subsequent visits. There was no 
statistically significant difference between two groups indicating both the drugs 
are equally efficacious.  
 
Comparison of percentage predicted from forced expiratory volume at the 
end of 1 second 
 Doxofylline Deriphylline P value 
Baseline 59.96±1.68 59.76±4.68 0.72 
I visit 67.02±2.04 66.5±4.16 0.314 
II visit 73.03±3.55 72.98±3.2 0.93 
III visit 77.51±6.57 77.42±2.24 0.94 
 
Table 11: Forced Expiratory Volume At The End Of 1 Second 
 
 
 
  
 
Figure 19: Forced Expiratory Volume At The End Of 1 Second
 
Doxofylline 
Deriphylline 
Table 12: Forced Expiratory Volume At The End Of 1 Second
 Percentage predicted about forced expiratory volume at
spirometric parameter which showed no significant differen
groups of study while 
baseline to the III visit.
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Baseline III visit 
59.96±1.68 77.51±6.57 
59.76±4.68 77.42±2.24 
 
Improvement From Baseline 
 
there was significant improvement in both groups from the 
 
 
Visit I Visit II Visit III
67.02
73.03
77.51
66.5
72.98
Doxofylline Deriphylline
 
 
P value 
0.0001 
0.0001 
-  
1 second is a 
ce between both 
77.42
  
 
Comparison of percentage of predicted peak expiratory flow rate in both 
the study group: 
 
Baseline 
I visit 
II visit 
III visit 
Table 13: Peak Expiratory Flow Rate
Figure 
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Table 14: Peak Expiratory Flow Rate
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60.62
68.38
71 
Doxofylline Deriphylline 
60.62±1.99 68.38±5.68 
67.33±3.38 67.81±4.36 
71.89±3.66 71.84±3.56 
76.83±4.66 76.84±2.78 
 
 
 
 
20: Peak Expiratory Flow Rate 
 
Baseline III visit 
60.62±1.99 76.83±4.66 
68.38±5.68 76.84±2.78 
 
- Improvement From Baseline
Visit I Visit II Visit III
67.33
71.89
76.83
67.81
71.84
P value 
0.225 
0.973 
0.92 
0.99 
P value 
0.0001 
0.0001 
 
76.84
Doxofylline
Deriphylline
  
 
 The results of peak expiratory flow rate suggests that there exists 
significant improvement in Doxofylline as well as deriphylline group 
participants compared to the baseline. There is no significant difference seen in 
the efficacy between the two study groups statistically which implies the two 
groups are equally efficacious.
 
Comparison of FEV1
 Doxo
Baseline 
I visit 
II visit 
III visit 
Table 15: Comparison of FEV
Figure 21
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/FVC of both the study group patients:
fylline Deriphylline 
62.91±1.93 62.58±3.8 
66.56±3.47 66.51±3.63 
73.6±3.77 73.58±3.21 
77.22±4.63 77.25±2.74 
 
1/FVC 
 
: Comparison of FEV1/FVC 
FEV1/FVC1 Visit I FEV1/FVC2  Visit 
II
FEV1/FVC3  Visit 
III
66.56
73.6
77.22
66.51
73.58
 
P value 
0.48 
0.93 
0.96 
0.96 
 
77.25
Doxofylline
Deriphylline
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 Baseline III visit P value 
Doxofylline 62.91±1.93 77.22±4.63 0.0001 
Deriphylline 62.58±3.8 77.25±2.74 0.0001 
 
Table 16: Comparison of FEV1/FVC - Improvement From Baseline 
 
 Analysis of FEV1/FVC of the study population showed that there was 
significant improvement in both the groups when compared with the base line. 
At the same time there was no significant difference between both the groups in 
terms of efficacy. 
 
ESTIMATION AND COMPARISON OF SAFETY PROFILE 
Adverse reactions encountered among the participants 
 10% of the Doxofylline group  participants had adverse reactions while 
22% of Deriphylline group had the same. The incidence of adverse reactions 
were significantly high in deriphylline group with a P value of < 0.001. 
 
 
DOXOFYLLINE GROUP DERIPHYLLINE GROUP P value 
ADR No. of Patients Percentage No. of Patients Percentage 
NIL 73 91.2 18 22.5 
<0.001 
Epi gastric pain 2 2.5 7 8.8 
Giddiness 2 2.4 4 5 
Nausea 2 2.5 14 17.5 
Palpitation 1 1.2 8 10 
Headache - - 10 12.5 
Insomnia - - 4 5 
Tachycardia - - 2 2.5 
Tremor - - 10 12.5 
Vomiting - - 3 3.8 
Total 80 100 80 100 
Table 17: Adverse reactions encountered among the participants 
 
  
 
Figure 22: Deriphylline Group 
Figure 23: Doxofylline Group 
 
 Adverse reactions like vomiting, tremor, tachycardia, insomnia, head ache 
etc. are not seen in doxofylline group. 
and palpitation are less in doxofylline
13%
5%
3%
ADR IN DERIPHYLLINE GROUP
74 
- Adverse Reactions Among The 
Participants 
 
 
- Adverse Reactions Among The Participants
Also epigastric pain, giddiness, 
 group compared with deriphylline group.
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HEADACHE
INSOMNIA
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nausea 
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 The management of adverse reactions is done by appropriate therapy; 
with H2 receptor antagonists, Proton pump inhibitors, antihistaminics etc. 
 
Comparison of laboratory investigations: 
 The laboratory investigations done at the baseline and at the end of the 
study period showed no significant difference in the parameters tested. 
 
ECG: 
 The baseline ECG in both groups were within normal limits. During the 
course of study, 3 participants in deriphylline group had sinus tachycardia  in the 
ECG which was managed conservatively. The doxofylline group patients had no 
such abnormalities in the ECG. 
 
CHEST X-RAY: 
 At the start of study, chest x-ray of 3 patients in deriphylline group and 2 
patients in doxofylline group had changes suggestive to hyperventilation, which 
persisted till the end of the study. The CXR of the other patients were within 
normal limits at the beginning and end of the study. 
 
ESTIMATION OF COST: 
 The estimation of treatment cost was done by summing up the direct and 
indirect costs. The direct cost included the cost of treatment of disease, adverse 
events and investigations. The indirect cost accounted for travelling expenses, 
food expenses and loss of wages of the patient and the accompanying person. 
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COMPARISON OF TOTAL COST: 
 Doxofylline Deriphylline P value 
Mean cost for 3 months 
(in rupees) 503.99±131.4 205.09±160.47 0.00 
 
Table 18: Comparison Of Total Cost 
 
 In this study, the mean cost for treating a patients with doxofylline was 
significantly more than that of deriphylline. 
 
Figure 24: Treatment Cost 
 
 One year mean expense of treating a patient with doxofylline was 
Rs.2016 ±524.59 while that of deriphylline was Rs.1000.30 ± 641.91. The mean 
cost for treating a patients with doxofylline was significantly higher (P=0.0001). 
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Figure 25: Expense For 1 Year 
 
ESTIMATION OF EFFECTIVENESS: 
 In this study, the effectiveness is estimated as significant asthma control.  
 
COMPARISON OF EFFECTIVENESS: 
 Both the study drugs provide significant improvement in bronchial 
asthma patients. There was no statistically significant difference between both 
study group in terms of effectiveness. The patients treated with doxofylline 
experienced less adverse events while the patients in the deriphylline group 
witnessed statistically significant increase in the adverse reactions. 
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DISCUSSION 
 Bronchial asthma is a chronic airway inflammatory disease with a 
worldwide prevalence of 1-18%.  Variety of triggers  are attributed to its 
causation. The disease brings about variable airflow limitation which results in 
wheeze, shortness of breath, chest tightness and cough. 
 
 The pharmacotherapy consists of relievers, controllers and add-on 
therapies. Methylxanthines are used as reliever medication and can be used 
conveniently in oral route.  In developing countries like India, oral 
methylxanthines are the commonly used drug in the population level. To obtain 
data about methylxanthines with bronchodilatory properties, less adverse 
reactions and at a lower cost, this study is conducted. 
 
 This prospective observational study of efficacy, safety and cost 
effectiveness of doxofylline and deriphylline in mild to moderate persistent 
bronchial asthma patients, involved 160 patients. The diagnosis was done in 
proportion to the guidelines of global strategy for diagnosis and prevention of 
bronchial asthma, update -2014.    
 
 The enrolment was done after obtaining written informed consent. It was 
conducted in the Thoracic medicine department of Chengalpattu medical college  
for a duration of 12 weeks over a period of 1 year. The participants were 
evaluated and analyzed for epidemiological profile, disease activity, efficacy, 
safety  and cost effectiveness parameters. 
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 The mean age of the participants in doxofylline group was 45 years and 
that of deriphylline group was 44 years. Doxofylline group had bronchial asthma 
for the mean duration of 6.97±3.57 years and the deriphylline group patients had 
the illness for a mean duration of 7.46±4.63 years. 
 
 Aggravating factors are present in 75% of patients under doxofylline and 
77.5% of patients under deriphylline treatment. Dust, cold weather and  air 
pollution were attributing factors of illness. 
 
 Family history of bronchial asthma was present in 25% of patients in 
doxofylline group and 28% in deriphylline group. There is a positive association 
between the presence of asthma in the family and development of airway hyper 
responsiveness as established by studies done by Blair.s.et al., and young s.et.al, 
 
 A mean BMI OF 21.39 is seen in patients with doxofylline therapy and a 
BMI of 21.69 is seen in patients on deriphylline therapy. 
 
EFFICACY PARAMETERS: 
 Assessment of Asthma Control Test questionnaire showed statistically 
significant improvement in all the study participants when compared with the 
baseline. The study further showed a significant difference between the two 
groups.  The fact that there was better asthma control in doxofylline group than 
deriphylline group. The finding coincides with the study done by Patel yet al. on 
bronchial asthma using controller medications as add-on therapy to ICS and 
LABA.  They used montelukast, doxofylline and increased dose of ICS in their 
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study.110 ACT can be used in primary care settings to judge the asthma control. 
This tool can be easily used by trained personnel.111 
 
 Analysis of subjective rating of asthma control revealed that there was 
statistically significant improvement from the baseline rating to the end of study 
rating. The significant improvement in doxofylline group over the deriphylline 
group indicates that doxofylline had better control over bronchial asthma. This 
result is consistent with the study conducted by Gold stein MF et. al. They did a 
double blinded placebo controlled multicentric clinical trial   involving 346 
patients having bronchial asthma. This study showed that there was significant 
reduction  in the frequency of asthma with doxofylline 400mg as compared to 
that of  theophylline  (P<0.05)112 
 
 Spirometry parameters measured in this study demonstrated significant 
improvement in both the groups comparing the baseline and the end values of 
the study (P=0.0001). No statistically significant difference established between 
the two groups. Comparing the baseline parameters to the study end parameters 
we got 19% and 28 % improvement in FVC, 17% improvement in FEV, 16% 
and 8% improvement in PEFR and FEV1/FVC ratio improved by 15. A 
randomized controlled trial was done by Dolcetti et al. compared  doxofylline 
and placebo. The results of that study indicated a significant improvement in 
FEV1 (<20%after 2 hrs.) as compared to the baseline.112Another double blinded 
randomized multicentric trail conducted by Melillo.G et al. showed significant 
improvement in spirometry parameters with doxofylline and Theophylline.113 
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SAFETY PARAMETERS: 
 The clinical use of methylxanthines are restricted due to its adverse effect 
profile. Hence there is a constant search for a newer drug with less incidence of 
adverse events. In this study, doxofylline had a lower number of adverse events 
compared with deriphylline. Adverse reactions are encountered in 10% of 
doxofylline and 22% of deriphylline group.  The adverse events like epigastric 
pain, giddiness, nausea, palpitation are seen only in deriphylline group and not in 
doxofylline group. Decrease in incidence of adverse reactions in doxofylline 
group ensures the increase in safety of its utility. In a study done by Bossi.F. et 
al. doxofylline showed a better tolerability than theophylline.113, 114. The 
suggested reasons for this are its lower affinity towards A, and A2 adenosine 
receptors, it does not interfere with calcium influx, and also it does not 
antagonize calcium channel antagonists. These characters distinguish 
doxofylline from deriphylline .In therapeutic dose doxofylline is a less cardiac 
stimulant than deriphylline. It does not increase the cardiac frequency nor is 
arrhythmogenic.115  
 
 Deriphylline increases the gastric acid, pepsin secretion and the 
gastrointestinal motility. As this also plays a role in reducing the pressure in 
inferior oesophageal sphincter, patients on deriphylline suffer with 
gastroesophageal reflux disease. Doxofylline has fewer gastrointestinal side 
effects and tolerated well by the patients with acid peptic disorder.116 
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 Deriphylline alters the pattern and quality of sleep leading insomnia and 
frequent wakening. The study conducted by Sacco et al., the patients on 
theophylline experienced double the number of arousals than that of subjects 
without any medications. This reduced quality of sleep does not exist with the 
use of doxofylline, which again contributing better tolerability of doxofylline 
than theophylline.117 
 
 Goldstein and Cherrinsky conducted a study which showed doxofylline of 
dose 1200mg/day had lower dropout rates due to adverse reactions compared 
with theophylline group.77 a study conducted in paediatric population   by 
Bagnato et al. with doxofylline showed 11% adverse effects118 which matches 
with the observation of our study showing 10% adverse reactions in doxofylline 
group.      
 
COST EFFECTIVENESS 
 The mean total cost of treating a patient with doxofylline was Rs.504 and 
for deriphylline was Rs.250 in the study period. The higher expense of treating 
with doxofylline was due to its higher cost. Even though we spent extra cost in 
treating the more number of adverse effects encountered by deriphylline group 
patients, this expense was surpassed by the cost of doxofylline. In developing 
countries owing to the higher cost of treatment with doxofylline, we can opt 
deriphylline which is equally efficacious at the population level. Doxofylline can 
be reserved for use in selected patients who cannot tolerate or encounter more 
adverse reactions due to deriphylline. 
Conclusion   
and  
Summary 
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CONCLUSION AND SUMMARY 
 
 Asthma is a chronic disease with worldwide prevalence affecting all age 
groups contributing to the health care burden of the society. A lot of novel 
medications have been introduced and current guidelines suggest the use of anti-
inflammatory therapy in all patients with chronic or persistent asthma. 
Corticosteroids, mast cell stabilizers, leukotriene receptor antagonists and 
methylxanthines are effective preventive therapy. Methylxanthines have 
bronchodilator, immunomodulation, mucoregulator, anti-inflammatory, 
inflammatory cell stabilizing and steroid sparing properties. They can be used as 
combination therapy with inhaled steroids in the treatment of mild to moderate 
persistent bronchial asthma. 
 
 The present study done at the Thoracic Medicine Department, 
Chengalpattu Medical College hospital is a prospective open labeled study 
comparing doxofylline and deriphylline in 160 patients of mild to moderate 
persistent bronchial asthma .The patients were assessed for epidemiological 
profile, spectrum of disease, efficacy, safety and cost effectiveness. 
 
 This study revealed that the treatment with both doxofylline and 
deriphylline resulted in significant bronchodilatation compared to the baseline. 
Regarding efficacy, doxofylline was better than deriphylline in subjective 
parameters of asthma control test questionnaire and subjective rating of asthma 
control but had equal efficacy with spirometric parameters. 
  
84 
 
 
 In terms of safety, doxofylline was significantly safe compared to 
deriphylline. The frequently observed adverse effects were nausea, insomnia in 
both study groups. Tachycardia, palpitation, epigastric pain, vomiting were the 
other untoward   effects seen with deriphylline and not noted in doxofylline. 
 
 The cost effective analysis revealed that deriphylline was the cheaper and 
cost effective methylxanthene for the treatment of bronchial asthma in 
developing countries at population level. Doxofylline even though costlier had 
better safety profile with less adverse reactions compared to deriphylline on 
individual based approach. 
 
LIMITATIONS OF THE STUDY 
1. Larger sample size would be considered for better results. 
2. Plasma drug concentrations and other pharmacokinetic parameters were not 
done due to the cost. 
3. Daily monitoring with peak flow meter was not done due to logistics and 
cost. 
4. Incremental cost effectiveness ratio is not calculated since it was not feasible 
in the present setup. 
 
SCOPE FOR FURTHER RESEARCH 
1. Pharmacokinetic parameters including plasma drug concentrations of various 
methylxanthines can be assessed for efficacy, safety and tolerability. 
2. Pharmacoeconomic analysis can be done on a large sample of population 
involving multiple centres.  
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 Annexures 
ANNEXURE I 
STUDY PROFORMA 
DATE: 
PATIENT INFORMATION: 
NAME:                                                                                  IP/OP No.: 
AGE: yrs.                                                                                    Ht 
GENDER: Male / Female.                                                           Wt: 
OCCUPATION:                                                                        BMI:  
ADDRESS: 
PHONE NUMBER: 
HISTORY: 
DURATION OF THE ILLNESS: 
COUGH: 
BREATHLESSNESS: 
CHEST TIGHTNESS: 
WHEEZE: 
PRECIPITATING/AGGRAVATING FACTORS: 
1. DUST IN THE ENVIRONMENT: YES / NO 
2. CIGARETTE SMOKE: YES / NO 
3. COLD WEATHER: YES / NO 
4. AIR POLLUTION: YES / NO 
  
 SIGNIFICANT PAST HISTORY: 
PERSONAL HISTORY: 
HISTORY OF ALLERGY: 
FAMILY HISTORY OF BRONCHIAL ASTHMA: YES/ NO 
GENERAL PHYSICAL EXAMINATION: 
VITALS: 
PULSE RATE: 
BLOOD PRESSURE: 
RESPIRATORY RATE: 
SYSTEMIC EXAMINATION: 
CVS 
RS 
P/A 
CNS   
 
  
ASTHMA CONTROL TEST 
To complete it, please mark √ in the one box that best describes your answer. 
1. In the past 4 weeks, how much of the time did your asthma keep you from getting 
as much done at work, school or at home? 
All of the 
time  
Most of the 
time   
Some of the 
time   
A little of the 
time     
None of the 
time 
1       ⁮ 2 3 4 5 
 
2. During the past 4 weeks, how often have you had shortness of breath?   
More than   once a 
day           
Once a 
day 
3 to 6 times a 
week                               
Once or twice  a 
week                               
Not at 
all    
1       ⁮ 2 3 4 5 
 
3. During the past 4 weeks, how often did your asthma symptoms (wheezing, 
coughing, shortness of breath, chest tightness or pain) wake you up at night or earlier 
than usual in the morning?  
4 or more nights a 
week 
   2 to 3  nights a 
week                         
Once a 
week          
Once or twice  a 
week                               
Not at 
all   
1       ⁮ 2 3 4 5 
 
4. During the past 4 weeks, how often have you used your rescue inhaler or nebulizer 
medication (Salbutamol)? 
3 or more times 
per day           
1 or 2  times 
per day                             
2 or 3  times per 
week or less                 
Once  a 
week                               
Not at 
all
1       ⁮ 2 3 4 5 
 
5. How would you rate your asthma control during the past 4 weeks? 
Not at all 
Controlled    
Poorly 
Controlled 
Somewhat 
Controlled                
Well 
Controlled 
Completely 
Controlled 
1       ⁮ 2 3 4 5 
 
To score the ACT 
Each response to the 5 ACT questions has a point value from a 1 to 5 as 
shown on the form.To score the ACT, add up the point values for each response to all 
five questions. 
  
SUBJECTIVE RATING OF ASTHMA CONTROL BY THE PATIENT                                  
SINCE PREVIOUS VISIT 
Baseline  
…………………………………………………………………………………. 
0%                                                50%                                                     100% 
1st visit  
…………………………………………………………………………………. 
0%                                                50%                                                     100%  
2nd visit 
 ………………………………………………………………………………. 
0%                                               50%                                                      100% 
3rd visit  
…………………………………………………………………………………. 
0%                                               50%                                                      100%                      
 
USE OF RESCUE MEDICATION  
NEED FOR RESCUE MEDICATION IN THE PAST 4 
WEEKS 
1ST VISIT 
2ND VISIT 
3RD VISIT 
  
                                   SPIROMETRIC PARAMETERS  
A] SPIROMETRIC RESULTS AT THE BASELINE                                             
DATE:  
PARAMETERS   PREDICTED   PREBD  %PREDICTED  POST-BD       
%CHANGE  
FVC 
FEV1 
FEV1 % 
PEFR 
B] SPIROMETRIC RESULTS AT THE END OF 4 WEEKS                               
DATE: 
PARAMETERS      PREDICTED      ACTUAL         %PREDICTED 
FVC 
FEV1 
FEV1 % 
PEFR 
 
C] SPIROMETRIC RESULTS AT THE END OF 8 WEEKS                                  
DATE: 
PARAMETERS      PREDICTED      ACTUAL       %PREDICTED 
FVC 
FEV1 
FEV1 % 
PEFR 
D] SPIROMETRIC RESULTS AT THE END OF 12 WEEKS                      DATE: 
PARAMETERS     PREDICTED     ACTUAL           %PREDICTED 
FVC 
FEV1 
FEV1 % 
PEFR 
  
LABORATORY INVESTIGATIONS 
INVESTIGATIONS                    BASELINE              AT THE END OF STUDY 
COMPLETE HAEMOGRAM 
Hb 
RBC Count 
WBC Count 
Platelet Count 
RENAL FUNCTION TESTS 
S.Creatinine 
Blood urea 
LIVER FUNCTION TESTS 
SGOT 
SGPT 
CT 
BT 
Random Blood Sugar 
Chest X- 
 
 
  
   
   
ANNEXURE II 
INFORMED CONSENT FORM 
Title of the study : Efficacy, safety and cost effectiveness of oral Doxofylline and 
Theophylline for mild to moderate persistent bronchial asthma:  
A randomized retrospective open labeled comparative study. 
Name of the Participant 
Name of the Principal, Co-Investigator: Dr.M.Nandhini Priya, Dr.Purushothaman 
Name of the Institution: The Chengalpattu Medical College 
Name and address of the sponsor / agency (ies) (if any):  Nil 
Documentation of the informed consent 
I                                    have read the information in this form (or it has been read to 
me).I was free to ask any questions and they have been answered. I am over 18 years 
of age and, exercising my free power of choice, hereby give my consent to be 
included as a participant in Efficacy, safety and cost effectiveness of oral Doxofylline 
and Theophylline for mild to moderate persistent bronchial asthma- a randomized 
prospective open labeled comparative study 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have been informed the investigator of all the treatments I am taking or have 
taken in the past________ months including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this study.* 
7. I agree to cooperate with the investigator and I will inform him/her immediately if 
I suffer unusual symptoms.* 
8. I have not participated in any research study within the past ________month(s).* 
9. I have not donated blood within the past _______ months—Add if the study 
involves Extensive blood sampling. * 
10. I am aware of the fact that I can opt out of the study at any time without having to 
give any reason and this will not affect my future treatment in this hospital. * 
11. I am also aware that the investigator may terminate my participation in the study 
at any time, for any reason, without my consent. * 
12. I hereby give permission to the investigators to release the information obtained 
from me as result of participation in this study to the sponsors, regulatory 
authorities, Govt. agencies, and IEC. I understand  that they are publicly 
presented. 
13. I have understand that my identity will be kept confidential if my data are publicly 
presented 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. I am aware that if I have any question 
during this study, I should contact the investigator. By signing this consent form I 
attest that the information given in this document has been clearly explained to me 
and understood by me, I will be given a copy of this consent document 
 
For adult participants: 
Name and signature / thumb impression of the participant (or legal representative 
 if participant incompetent) 
Name _____________________ Signature_________________ Date__________ 
Name and Signature of impartial witness (required for illiterate patients) 
Name _____________________ Signature_________________ Date__________ 
Address and contact number of the impartial witness 
 
   
ANNEXURE III 
Information to Participants 
Sponsor: Nil 
Investigator (principal and at least one Co-investigator):  Dr.M.Nandhini Priya, 
Dr.Purushothaman 
Name of Participant 
Title:  Efficacy, safety and cost effectiveness of oral Doxofylline and 
 Theophylline for mild to moderate persistent bronchial asthma: A randomized 
 prospective open labeled comparative study. You are invited to take part in this 
research/ study /procedures. The information in this document is meant to help you 
decide whether or not to take part. Please feel free to ask if you have any queries or 
concerns. 
You are being asked to participate in this study being conducted in __ Chengalpattu 
Medical College     
Purpose of the Research 
Bronchial asthma is a chronic inflammatory disorder characterized by airway hyper 
responsiveness that leads to recurrent episodes of wheezing, breathlessness, chest 
tightness, and coughing particularly at the night or early morning. Often associated 
with variable, widespread obstruction that is reversible either spontaneously or with 
treatment1,2. 
We want to test the efficacy and safety of a new drug  in these diseases  
We have obtained permission from the Institutional Ethics Committee 
The Study Design 
The study subjects will be randomly allocated into two groups of 60 patients each. 
Demographic data, history, clinical examination and details of drug prescription by 
the treating physician will be recorded in the study proforma. Group 1 patients will be 
treated with Doxofylline 400mg once daily and group 2 patients will be treated with 
Theophylline twice daily. The patients will be followed for 12 weeks. Relevant lab 
investigations will be done at the beginning and at the end of the study. The schedule 
of patient visit is as follows Visit 1/ day1 / initial or baseline assessment and follow-
up at 4, 8 & 12 weeks. 
At each visit, the study physician will examine you. Some test will be carried out at 
each visit. Blood collection involves prick with a needle and syringe. 
In addition, if you notice any physical or mental changes, you must contact the 
persons listed at the end of the document. [You will be required to return unused 
study medicines when you report for your scheduled visits. This will enable correct 
assessment of the study results.]You may have to come to the hospital (study site) for 
examination and investigations apart from your scheduled visits, if required. 
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your medical 
information (personal details, results of physical examinations, investigations, and 
your medical history). By signing this document, you will be allowing the research 
team investigators, other study personnel, sponsors, IEC and any person or agency 
required by law like the Drug Controller General of India to view your data, if 
required. The information from this study, if published in scientific journals or 
presented at scientific meetings, will not reveal your identity. 
Possible benefits to other people 
The result of the research may provide benefits to the society in terms of  
advancement of medical knowledge and/or therapeutic benefits to future patients. 
How will your decision to not participate in the study affect you? 
Your decisions to not participate in this research study will not affect your medical 
care or your relationship with investigator or the institution. Your doctor will still  
take care of you and you will not loose any benefits to which you are entitled. 
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the right to  
withdraw from this study at any time during course of the study without giving any 
reasons. However, it advisable that you talk to the research team prior to Stopping the 
treatment. 
 
 
 
 
  
   
DOXOFYLLINE GROUP 
History and general examination 
S.NO. AGE SEX OCCUPATION DURATION OF ILLNESS AGE RAATDING FACTORS FAMILY HISTORY BMI 
1 40 M TAILOR 4 DUST - 20.1 
2 59 M - 10 COLD WEATHER BA 21.2 
3 58 M - 12 COLD WEATHER - 19.4 
4 50 M MILK VENDER 10 DUST ALLERGY 20.6 
5 57 M SECURITY 4 DUST - 21.4 
6 46 M CARPENTER 8 DUST - 19.8 
7 52 F - 10 COLD WEATHER - 29.4 
8 54 M AGRICULTURE 15 DUST - 19.9 
9 47 F - 10 COLD WEATHER BA 21.4 
10 35 F CONSTRUCTION WORKER 3 DUST - 22.3 
11 41 F HOUSEMAID 5 DUST - 20.6 
12 52 M SHOP KEEPER 7 DUST - 21.5 
13 37 F CLERK 5 - - 22.7 
14 56 F - 10 COLD WEATHER BA 28.6 
15 39 M CIVIL CONSTRUCTION WORKER 4 DUST - 19.8 
16 42 M GARDENER 7 - - 19.1 
17 27 F RECEPTIONIST 2 - - 20.3 
18 48 M FACTORY WORKER 8 AIRPOLLUTION - 21.5 
19 42 M AUTO DRIVER 3 - - 22.7 
20 37 F AGRI COOLI 5 DUST - 23.4 
21 40 F FISH SELLER 7 - - 29.2 
22 51 M COOLI 6 - - 19.6 
23 27 M MECHANIC 2 - - 20.5 
24 44 F CONSTRUCTION WORKER 10 DUST BA 21.7 
25 38 F - 3 - - 22.9 
26 54 F - 8 COLD WEATHER BA 28.1 
27 54 M SHOP WORKER 6 - - 19.2 
28 39 M FISHERMAN 7 - - 19.6 
29 47 M CABLE OPERATOR 5 - - 20.4 
30 49 M AGRI COOLI 10 DUST - 21.8 
 
DOXOFYLLINE GROUP 
History and general examination 
 
 
 
  
S.NO. AGE SEX OCCUPATION DURATION OF ILLNESS AGE RAATDING FACTORS FAMILY HISTORY BMI 
31 52 F VEGETABLE VENDER 12 COLD WEATHER BA 27.4 
32 42 M AUTO DRIVER 7 - - 19.2 
33 53 F HOUSEMAID 10 DUST - 18.4 
34 47 M CONSTRUCTION COOLI 10 DUST - 18.6 
35 35 F CLERK 3 DUST - 18.2 
36 56 F - 10 COLD WEATHER BA 19.4 
37 42 M CONSTRUCTIO WORKER 7 DUST - 20.8 
38 41 F HOUSE MAID 4 DUST - 21.7 
39 50 F HOUSE  MAID 7 DUST - 20.6 
40 48 M FACTORY WORKER 8 AIR POLLUCTION - 22.3 
41 47 M DRIVER 10 COLD WEATHER BA 19.3 
42 33 F TEA STALL 2 DUST - 18.8 
43 49 M AGRICULTURE FORMER 9 DUST - 19.4 
44 54 F - 12 COLD WEATHER BA 28.8 
45 39 M MECHANIC 5 DUST BA 19.2 
46 42 M PETROL BUNK 7 AIR POLLUCTION - 20.4 
47 48 M CONTRUCTION WORKER 8 DUST - 18.6 
48 36 F - 3 DUST - 22.4 
49 29 M PAINTER 2 AIR POLLUCTION - 19.1 
50 39 F AGRI COOLI 8 DUST BA 18.8 
51 42 M HOTEL SERVICE 12 COLD WEATHER BA 21.4 
52 55 F - 15 COLD WEATHER BA 29.4 
53 49 M MILK VENDER 4 DUST - 19.7 
54 38 F GROSSARY SHOP 2 DUST - 20.1 
55 47 M FACTORY WORKER 10 AIR POLLUCTION - 18.6 
56 52 M FARMER 12 DUST BA 22.6 
57 43 F CATTLE REARING 8 DUST - 19.8 
58 47 M GARDENER 4 DUST - 20.2 
59 40 F SHOP KEEPER 3 DUST - 19 
60 52 M SECURITY 3 COLD WEATHER - 22.8 
DOXOFYLLINE GROUP 
History and general examination 
 
S.NO. AGE SEX OCCUPATION DURATION OF ILLNESS AGE RAATDING FACTORS FAMILY HISTORY BMI 
61 40 M CARPENTER 7 DUST - 24.1 
62 53 F VEGETABLE VENDER 10 COLD WEATHER BA 28.1 
63 44 M ELECTRICIAN 8 DUST - 23.4 
64 47 M PETROL BUNK 2 AIR POLLUCTION - 21.2 
65 36 F - 3 DUST - 22.1 
66 54 F FISH VENDER 6 DUST - 18.6 
67 50 M LAUNDRY 10 - - 19.2 
68 43 F HOUSE MAID 5 - - 18.8 
69 37 M GARDENER 3 yrs DUST - 18.2 
70 42 M DOBHI 10  yrs DUST Yes (BA) 21.4 
71 38 M CONSTRUCTION WORKER 3  yrs DUST - 17.8 
72 45 F - 4  yrs - - 24.6 
73 57 M - 10  yrs COLD WEATHER Yes (BA) 19.2 
74 59 M - 12  yrs COLD WEATHER Yes (BA) 18.4 
75 50 M LAUNDRY WORKER 15  yrs AIR POLLUCTION - 23.2 
76 52 M AGRI COOLI 12  yrs DUST / COLD WEATHER Yes (BA) 20.1 
77 49 M SHOPKEEPER 4  yrs DUST - 29.6 
78 40 M FACTORY WORKER 6  yrs AIR POLLUCTION - 21.2 
79 42 M SECURITY 4  yrs COLD WEATHER - 19.8 
80 38 M HOUSE MAID 5  yrs DUST - 18.2 
 
  BA-bronchial Asthma 
  BMI-Body 
 
 
  
DOXOFYLLINE GROUP 
Efficacy and safety 
S.NO. ACT SCORE SUBJECTIVE RATING FVC % PREDECTED FEV 1 PEFR FEV 1/FVC ADRS 
0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 
 
1 15 16 20 21 45 60 75 85 58 64 72 80 59 70 72 71 59 70 68 70 64 67 71 73 
 
2 17 18 19 23 55 55 80 80 62 68 80 83 61 66 71 72 58 71 65 78 60 62 68 81 
 
3 15 16 20 22 45 65 75 85 60 67 74 80 60 68 72 60 64 66 74 75 63 72 74 75 NAUSEA 
4 16 17 21 21 45 70 70 85 63 71 81 82 58 64 65 61 61 72 72 72 62 71 77 72 
 
5 15 16 21 23 50 60 80 80 55 70 76 81 62 67 60 72 60 72 71 81 65 62 68 87 
 
6 16 17 19 21 50 60 75 85 62 68 72 79 58 66 68 73 58 60 70 73 61 68 76 82 
 
7 17 19 20 22 55 65 80 80 64 71 74 80 61 68 74 75 58 67 69 75 66 61 73 71 
 
8 15 18 19 23 45 60 75 90 61 70 78 83 60 64 75 72 59 66 75 81 64 63 79 76 
 
9 15 16 20 22 45 65 80 85 63 68 80 82 58 66 71 82 62 70 74 81 62 60 76 80 
 
10 17 19 21 21 55 55 75 90 65 71 76 81 62 65 70 70 63 62 65 72 60 68 63 72 
 
11 16 18 18 23 50 65 70 80 60 68 73 80 60 64 71 73 62 62 67 73 66 69 74 74 
 
12 17 19 20 21 55 60 70 85 55 72 78 80 61 69 72 72 64 66 74 75 63 61 75 72 
 
13 16 17 19 22 50 65 80 80 61 70 74 84 61 67 75 75 61 61 75 71 63 61 73 74 EPI GASTRIC PAIN 
14 17 17 21 23 55 70 70 85 58 68 72 82 59 66 74 70 60 71 63 73 66 65 75 74 
 
15 15 18 18 21 45 65 75 80 63 66 80 80 58 65 72 73 61 67 69 76 65 70 76 70 
 
16 16 19 19 22 50 60 80 90 60 68 76 81 59 68 73 86 59 72 73 74 62 63 68 73 
 
17 17 17 20 23 55 55 70 85 62 70 81 85 61 64 71 72 59 66 75 72 60 64 71 73 
 
18 16 18 18 21 50 65 80 80 55 72 78 80 60 65 65 82 58 68 67 72 63 68 72 81 
 
19 17 17 19 22 55 60 75 90 58 68 75 79 59 66 72 83 63 70 79 82 61 65 68 72 
 
20 15 16 18 23 45 65 70 85 60 66 74 78 58 68 70 83 63 72 71 81 64 69 78 75 
 
21 17 19 21 21 55 60 80 80 63 68 72 81 62 68 74 85 64 70 74 75 64 68 73 72 
 
22 16 17 18 22 50 70 70 90 76 67 80 82 60 64 75 73 62 69 72 75 65 68 69 74 
 
23 15 16 21 21 45 55 80 80 61 72 78 80 61 69 78 83 60 69 79 76 61 71 76 81 
 
24 15 18 19 23 45 65 75 90 55 68 76 79 61 69 70 82 61 72 70 72 60 63 78 70 
 
25 17 19 20 22 55 60 80 85 50 70 82 86 58 64 70 70 61 62 77 73 65 64 68 72 
 
26 16 17 21 23 50 70 70 90 58 66 74 80 59 66 71 71 58 71 76 75 64 70 79 84 EPI GASTRIC PAIN 
27 15 16 18 21 45 65 80 80 50 72 75 81 62 69 72 70 59 69 75 71 60 66 76 81 
 
28 17 18 19 22 55 60 75 85 63 67 78 83 60 70 75 73 64 67 71 74 63 62 73 72 
 
29 16 17 21 23 50 55 70 80 64 71 72 78 61 70 76 84 62 66 74 72 62 61 74 78 
 
30 17 18 20 21 55 65 80 90 62 68 80 80 59 68 65 83 63 69 74 72 64 69 71 74 
 
 
  
DOXOFYLLINE GROUP 
Efficacy and safety 
 
S.NO. ACT SCORE SUBJECTIVE RATING FVC % PREDECTED FEV 1 PEFR FEV 1/FVC ADRS 
0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 
 
31 15 17 18 23 45 60 75 90 60 69 74 81 59 66 75 84 61 60 73 74 66 68 68 79 
 
32 16 18 20 22 50 65 80 85 58 70 76 79 62 68 72 85 60 61 72 81 60 66 79 70 
 
33 15 16 19 21 45 60 75 80 60 67 72 84 61 69 74 86 59 65 70 76 65 65 75 83 
 
34 15 16 19 21 45 60 75 80 60 70 80 82 61 69 74 86 59 65 70 76 65 65 75 83 
 
35 15 17 22 22 45 55 75 80 62 65 75 81 60 69 71 84 64 67 68 70 61 69 75 75 
 
36 16 18 20 23 50 60 70 85 60 64 78 84 58 65 76 86 64 65 74 74 65 68 74 73 GIDDINESS 
37 17 17 21 23 55 65 75 85 58 67 80 79 61 70 78 82 62 66 71 73 63 64 77 78 
38 16 18 22 22 50 60 70 90 58 70 79 81 60 66 75 85 60 63 65 80 60 63 75 74 
39 17 18 22 23 55 60 75 90 61 66 76 84 62 68 72 84 60 62 77 78 66 69 78 73 
40 16 18 20 21 50 65 70 90 60 67 79 82 61 65 72 72 58 69 75 80 62 66 80 70 
41 15 18 21 23 45 70 80 90 58 64 77 78 59 69 77 73 58 72 74 81 64 61 77 73 
42 16 17 22 22 50 65 75 85 59 70 79 78 60 68 76 84 60 67 76 71 65 67 75 83 
43 17 20 20 23 55 65 75 90 60 68 78 80 58 70 75 73 61 66 70 75 61 63 76 81 
44 17 20 21 22 55 70 80 90 62 64 80 83 62 69 74 83 59 71 71 72 63 69 79 80 
45 16 18 22 23 50 60 80 85 61 69 76 81 60 67 72 71 62 68 75 74 60 69 78 77 PALPITATION 
46 16 20 20 21 0 65 75 85 58 70 74 84 61 64 72 84 60 71 74 76 62 67 80 72 
47 15 19 21 23 45 65 75 90 60 66 74 82 59 66 77 72 61 72 72 81 64 70 79 75 
48 16 20 22 22 50 60 70 85 61 66 76 79 59 64 74 86 59 68 75 82 63 68 77 73 
49 16 20 20 21 0 70 80 80 59 68 79 78 61 65 78 82 61 70 68 81 64 62 76 81 
50 15 18 21 22 50 70 80 80 62 67 77 81 62 69 75 84 62 71 65 77 63 60 68 80 
51 16 17 22 22 45 65 75 85 60 65 78 83 62 70 77 86 58 69 77 73 60 63 78 82 
52 15 20 20 21 45 60 80 90 62 68 78 84 60 66 71 85 61 62 71 82 64 66 76 76 
53 16 20 21 232 50 65 80 90 59 70 76 80 59 68 78 84 62 68 69 75 66 69 78 73 
54 15 19 22 22 45 65 80 90 59 64 75 81 59 65 80 72 60 61 75 81 61 71 79 77 
55 16 17 22 23 50 70 70 90 61 65 79 84 58 64 72 84 58 66 77 85 65 68 77 72 
56 17 19 20 21 55 70 75 85 62 69 74 79 58 67 77 82 62 64 71 86 63 70 73 73 GIDDINESS 
57 15 20 22 22 45 70 85 90 60 66 75 83 61 66 75 84 59 66 74 82 62 72 68 76 
58 16 17 22 23 50 65 70 85 58 69 80 80 62 69 79 72 60 63 65 74 64 68 76 82 
59 17 19 21 22 55 65 80 90 59 67 79 82 60 65 78 85 59 72 76 83 61 69 69 79 
60 16 19 22 23 50 70 70 85 58 65 77 84 61 68 77 82 61 68 68 81 60 68 70 79 
 
  
DOXOFYLLINE GROUP 
Efficacy and safety 
 
S.NO. ACT SCORE SUBJECTIVE RATING FVC % PREDECTED FEV 1 PEFR FEV 1/FVC ADRS 
0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 
 
61 15 19 20 21 45 70 80 90 61 67 75 83 59 64 72 72 60 70 77 86 64 66 79 84 
62 16 19 22 22 50 65 80 90 60 70 74 82 61 67 77 83 58 71 72 84 62 71 75 86 
63 17 20 22 23 55 65 75 85 62 64 79 83 58 66 72 74 62 69 71 73 63 69 80 83 
64 17 17 21 22 5 60 80 90 59 69 74 81 60 69 75 71 59 71 70 83 65 72 78 74 
65 16 19 20 21 50 65 75 85 59 65 76 82 62 66 78 73 62 68 70 85 66 69 71 79 
66 15 20 22 2 45 60 80 90 61 70 77 80 59 64 73 86 58 70 69 72 60 70 76 81 
67 16 17 22 23 50 70 75 85 60 69 79 83 58 70 75 83 61 71 74 81 62 72 71 75 
68 15 18 21 23 45 70 70 90 75 69 79 83 66 70 71 70 61 71 74 81 62 72 71 75 
69 19 19 20 21 70 70 80 85 62 70 77 84 60 64 72 73 62 70 79 82 64 69 78 83 
70 18 18 20 21 60 60 80 85 60 68 73 80 54 66 77 82 66 69 73 71 67 60 76 84 
71 17 18 19 20 60 16 70 80 64 71 75 79 60 68 70 74 64 72 70 73 62 62 72 81 
72 16 16 19 20 50 50 70 80 66 76 78 80 62 70 73 84 62 67 71 84 65 71 75 82 
73 17 18 18 20 60 60 60 80 61 72 76 81 58 69 72 76 60 69 74 83 63 61 78 78 
74 16 17 20 21 50 60 20 80 63 68 76 86 61 67 65 73 63 72 65 75 62 63 75 75 NAUSEA 
75 16 16 20 20 50 50 80 80 58 68 75 82 58 68 72 86 58 68 68 82 60 69 73 76 
76 16 18 20 22 50 60 80 85 64 74 78 86 59 70 72 84 62 70 73 75 61 67 76 84 
77 15 16 16 18 40 50 50 60 58 64 72 80 58 66 74 80 56 66 74 74 63 66 69 85 
78 17 17 19 20 60 60 70 80 65 76 78 84 62 65 71 70 60 70 71 73 62 68 77 83 
79 16 17 19 20 50 60 70 80 62 68 78 86 61 71 71 84 59 71 71 86 63 69 78 84 
80 17 18 20 22 60 60 80 85 60 68 76 82 58 65 70 71 61 69 70 71 61 69 77 82 
ACT- Asthma control test 
FVC-Force vital capacity 
FEV1- Forced expiratory volume in one sec 
PEFR-Peak expiratory flow rate 
ADRS- Adverse drug reactions 
 
  
 DOXOFYLLINE GROUP 
Cost effectiveness 
 
S.NO. 
DISTANCE 
FROM 
HEALTH 
FACILITY 
LOSS OF WAGES TRAVEL FOOD 
TOTAL 
ID INV 
DIRECT COSTS 
TMT OF 
ADR 
GRAND 
TOTAL PT ACP PT ACP PT ACP TMT TOTAL 
1 7 200 - 30 - 20 
 
250 
 
267.12 
  
517.12 
2 2 - 200 20 20 20 20 280 
 
267.12 
  
547.12 
3 4 - 150 20 20 20 20 230 
 
267.12 
 
12.13 509.25 
4 6 100 - 30 
- 
20 - 150 
 
267.12 
  
417.12 
5 12 100 - 40 
- 
30 - 170 
 
267.12 
  
437.12 
6 8 200 - 30 
- 
20 - 250 
 
267.12 
  
517.12 
7 7 - - 30 
- 
20 - 50 
 
267.12 
  
317.12 
8 15 150 - 60 
- 
70 - 280 
 
267.12 
  
547.12 
9 13 - 100 40 40 30 30 240 
 
267.12 
  
507.12 
10 3 70 - 20 
- 
20 - 110 
 
267.12 
  
377.12 
11 5 100 - 30 
- 
20 - 150 
 
267.12 
  
417.12 
12 7 150 - 30 
- 
20 - 200 
 
267.12 
  
467.12 
13 9 500 - 30 
- 
20 - 550 
 
267.12 
 
2.95 819.77 
14 11 - - 40 
- 
30 - 70 
 
267.12 
  
337.12 
15 13 100 - 40 
- 
30 - 170 
 
267.12 
  
337.12 
16 15 100 - 60 
- 
70 - 230 
 
267.12 
  
297.12 
17 17 500 - 60 
- 
70 - 630 
 
267.12 
  
897.12 
18 19 200 - 70 
- 
100 - 370 
 
267.12 
  
637.12 
19 20 200 - 70 
- 
100 - 370 
 
267.12 
  
637.12 
20 18 50 - 60 
- 
70 - 180 
 
267.12 
  
447.12 
21 16 100 - 60 
- 
70 - 230 
 
267.12 
  
497.12 
22 14 70 - 40 
- 
30 - 140 
 
267.12 
  
407.12 
23 12 150 - 40 
- 
30 - 220 
 
267.12 
  
487.12 
24 6 70 - 30 
- 
20 - 120 
 
267.12 
  
387.12 
25 8 - 140 30 30 20 20 240 
 
267.12 
  
507.12 
26 10 - - 40 
- 
30 - 70 
 
267.12 
 
2.95 340.07 
27 4 100 - 20 
- 
20 - 140 
 
267.12 
  
407.12 
28 2 200 - 20 
- 
20 - 240 
 
267.12 
  
507.12 
29 3 100 - 20 
- 
20 - 140 
 
267.12 
  
407.12 
30 7 50 - 30 
- 
20 - 100 
 
267.12 
  
367.12 
  
DOXOFYLLINE GROUP 
Cost effectiveness 
 
S.NO 
DISTANCE 
FROM 
HEALTH 
FACILITY 
LOSS OF WAGES TRAVEL FOOD 
TOTAL 
ID INV 
DIRECT COSTS 
TMT OF 
ADR 
GRAND 
TOTAL PT ACP PT ACP PT ACP TMT TOTAL 
31 9 100 - 30 
- 
20 - 150 
 
267.12 
  
417.12 
32 11 200 - 40 
- 
30 - 270 
 
267.12 
  
537.12 
33 13 100 - 40 
- 
30 - 170 
 
267.12 
  
437.12 
34 2 100 - 20 
- 
20 - 140 
 
267.12 
  
407.12 
35 6 500 
- 
30 
- 
20 - 550 
 
267.12 
  
817.12 
36 3 - 150 20 20 20 20 230 267.12 497.12 
37 9 100 - 30 - 20 - 150 267.12 417.12 
38 12 100 - 40 - 30 - 170 267.12 437.12 
39 15 200 - 60 - 70 - 330 267.12 597.12 
40 18 500 - 60 - 70 - 630 267.12 897.12 
41 20 300 - 70 - 100 - 470 267.12 737.12 
42 20 150 - 70 - 100 - 320 267.12 587.12 
43 16 - - 60 - 70 - 130 267.12 397.12 
44 12 200 200 40 40 30 30 540 267.12 807.12 
45 8 200 - 30 - 20 - 250 267.12 517.12 
46 4 200 - 20 - 20 - 240 267.12 507.12 
47 2 100 - 20 - 20 - 140 267.12 407.12 
48 3 - 500 20 20 20 20 580 267.12 847.12 
49 5 200 - 30 - 20 - 250 267.12 517.12 
50 7 50 - 30 - 20 - 100 267.12 367.12 
51 9 100 - 30 - 20 - 150 267.12 417.12 
52 11 - 200 40 40 30 30 340 267.12 607.12 
53 13 100 - 40 - 30 - 170 267.12 437.12 
54 15 100 - 60 - 70 - 230 267.12 497.12 
55 14 200 - 40 - 30 - 270 267.12 537.12 
56 17 150 - 60 - 70 - 280 267.12 547.12 
57 19 200 - 60 - 70 - 330 267.12 597.12 
58 3 100 - 20 - 20 - 140 267.12 407.12 
59 7 100 - 30 - 20 - 150 267.12 417.12 
60 6 100 - 30 - 20 - 150 267.12 417.12 
 
 
DOXOFYLLINE GROUP 
Cost effectiveness 
 
S.NO 
DISTANCE 
FROM 
HEALTH 
FACILITY 
LOSS OF WAGES TRAVEL FOOD 
TOTAL 
ID INV 
DIRECT COSTS 
TMT OF 
ADR 
GRAND 
TOTAL PT ACP PT ACP PT ACP TMT TOTAL 
61 5 200 - 20 - 20 - 240 267.12 507.12 
62 8 100 200 30 30 20 20 400 267.12 667.12 
63 2 200 - 20 - 20 - 240 267.12 507.12 
64 4 200 - 20 - 20 - 240 267.12 507.12 
65 6 100 - 30 - 20 - 150 267.12 417.12 
66 3 150 - 20 - 20 - 200 267.12 467.12 
67 11 200 - 40 - 30 - 270 267.12 537.12 
68 12 100 - 40 - 30 - 170 267.12 437.12 
69 2 100 - 20 - 20 - 140 267.12 407.12 
70 5 100 - 30 - 0 - 150 267.12 417.12 
71 8 100 - 30 - 20 - 150 267.12 417.12 
72 20 - - 70 - 100 - 170 267.12 437.12 
73 8 - 200 0 30 20 20 300 267.12 567.12 
74 16 - 150 60 60 70 70 410 267.12 12.13 689.12 
75 19 150 - 60 - 70 - 280 267.12 547.12 
76 12 50 - 40 - 30 - 120 267.12 387.12 
77 11 100 - 40 - 30 - 170 267.12 437.12 
78 17 200 - 60 - 70 - 330 267.12 597.12 
79 20 100 - 70 - 100 - 270 267.12 537.12 
80 15 100 - 60 - 70 - 230 267.12 497.12 
PT-pationt 
ACP-accompaning person 
ID-indirect cost 
TMT-treatment 
ADR-adverse drug reaction 
ECG-electro cardio graphy 
CXR-chest ex-ray 
HB-hemoclobin 
TC-total count 
RBS-random blood sugar 
BT-bleading time 
CT-clotting time 
 
 
 
DOXOFYLLINE GROUP 
Investigations 
 
S.NO 
ECG CXR HB % TC RBS SERUM CERATININE BL UREA SGOT SGPT BT CT 
0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 
1 N N N N 9.9 11.1 8340 7940 111 125 1.1 0.9 12.3 13.5 22.8 25.1 20 21 5 4.5 5.4 5.5 
2 N N N N 12.2 13 7935 7535 132 130 1 0.8 12 13.8 23 24.8 18 22 4.5 5.2 6 5.5 
3 N N N N 11.8 10.9 8890 8490 130 136 1 1.1 13.2 14 24.2 22.8 22 20 5.2 5.4 6.2 6.3 
4 N N Hyperventilation Hyperventilation 8.8 11.3 7137 6737 115 123 0.9 1 14 12.8 25 23.2 19 20 5.4 5 5.3 6 
5 N N N N 12.7 11.9 8769 8369 118 127 1 0.9 13.8 24 25.3 20 21 22 5 5.4 5.4 6.2 
6 N N N N 11.8 12.9 8964 8564 140 136 1.1 1.1 12.8 13.8 24 25.3 20 21 4.5 5 6 5.5 
7 N N N N 10.9 12.5 9002 8602 128 131 0.8 1 12.2 12.9 24.2 25 22 19 5.5 5.2 6 6.2 
8 N N N N 13 12.6 8433 8033 132 138 1 0.8 14 13.2 25 24.5 19 20 5 5.5 6.2 6.3 
9 N N N N 11.5 12.3 7762 7362 130 136 1.1 1 12.2 14 25.5 25.6 21 22 4.5 5.3 5.5 6 
10 N N N N 12.7 12.9 7346 6946 127 130 0.9 1 13.6 13.9 23 24.7 20 18 5.2 4.5 5.4 6.1 
11 N N N N 10.7 10.9 8347 7947 119 134 0.9 1.1 14 13.5 23 24.6 18 20 4.5 5 5.2 6 
12 N N N N 11 12.9 8879 8479 121 129 1 1.1 13.8 13 25.2 22.9 22 21 5 5.2 5.2 5.4 
13 N N N N 8.9 11.4 7943 7543 140 137 1.1 0.9 13 14 25.5 24 19 20 5.1 5.2 6 5.5 
14 N N N N 10.6 12.8 7811 7411 132 129 1.1 0.8 14 12.8 24.8 25.2 21 19 4.5 4.5 6.1 6.3 
15 N N N N 11.5 12.1 8762 8362 129 140 0.8 1.1 13.6 13 23.7 25.4 20 18 5.2 5 5.4 6.1 
16 N N N N 12 12.9 7969 7569 120 129 1.1 1 12.9 13.4 22.8 23.8 18 21 5.5 5.1 6.2 5.5 
17 N N N N 11.3 11.9 8365 7965 119 130 0.8 1 12 13.7 22.3 24 19 22 5 5.3 5.4 6 
18 N N N N 12.2 13.1 8436 8036 122 138 0.9 0.8 13.8 12.7 22 24.7 22 20 4.5 5 6 6.2 
19 N N N N 11.9 12.3 8538 8138 137 140 1.1 0.8 13.3 14 22.8 23.2 18 19 5.2 5.5 5.4 6.1 
20 N N N N 10.7 11.8 7895 7495 133 136 1 1.1 14 13.5 25 25.8 20 21 5.5 4.5 5.5 6 
21 N N N N 9.8 12.3 7689 7289 131 129 0.9 1 13.9 13 25.2 24.2 21 22 4.5 5 5.3 6.3 
22 N N N N 10.2 3 8969 8569 127 133 0.8 0.9 12.8 12.1 23.7 24.6 19 20 5.2 5.4 6.1 6 
23 N N N N 10.9 12.7 7978 7578 121 139 1 1.1 12 13.4 22.6 22.9 22 21 5 5.5 5.4 6.2 
24 N N N N 11.7 12.9 7999 7599 118 128 1.1 1 12.8 13.3 22.3 23.3 20 22 5.5 4.5 6.2 5.5 
25 N N N N 10.6 9.9 8092 7692 134 127 1.1 0.8 13.2 14 23.3 25.1 18 22 5.3 5 5.5 6 
26 N N N N 12.1 13 8819 8419 117 129 1 0.9 13 13.8 23.8 24.9 21 20 5 5.2 6 6.2 
27 N N N N 13.1 11.8 7947 7547 115 126 1.1 1.1 13.5 12.9 25.2 24 19 22 4.5 5.4 6.2 6 
28 N N N N 11.7 10.8 8238 7838 122 132 0.9 1 13.4 13 24 25.5 18 21 5 5.4 5.4 6 
29 N N N N 12.1 12.9 8891 8491 123 133 0.9 1.1 13.1 13.8 25.2 25.6 21 20 5.3 5.2 6 5.4 
30 N N N N 12.6 12.1 8139 7739 134 140 1.1 1 14 13.5 25.5 25 22 21 5.4 5 5.3 5.5 
 
 
 DOXOFYLLINE GROUP 
Investigations 
 
S.NO 
ECG CXR HB % TC RBS SERUM CERATININE BL UREA SGOT SGPT BT CT 
0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 
31 N N N N 12.4 11.9 7919 7519 129 136 1.1 0.9 12.9 12.8 23.3 24.2 20 22 5.5 4.5 6.2 6 
32 N N N N 10.9 12.1 7638 7238 139 132 0.8 1.1 13.7 13.8 23 25.6 18 21 5 5.2 6.1 6.2 
33 N N N N 11.8 12.5 8339 7939 125 133 0.9 1 13.2 14 22.8 24.6 19 21 4.5 5.3 5.3 6 
34 N N N N 11.7 13 7878 7478 137 130 1.1 0.9 12.9 13.2 22.6 24.3 21 19 5.5 5 6.1 6.2 
35 N N N N 8.2 10.1 8113 7713 119 131 0.9 1 13 12.8 23.8 24 18 20 5 5.5 5.3 6 
36 N N N N 9 11.2 7980 7580 137 129 1.0 1.1 13.8 12.9 22.6 25.5 22 22 4.5 5 5 5.4 
37 N N N N 9.7 12.1 8139 7739 126 130 1.0 1.1 12.9 13.2 24.5 25 19 20 5.5 5 5.2 6.2 
38 N N N N 12.1 13 8049 7649 120 129 0.9 0.8 14 13.8 25.1 25.5 21 22 5 4.5 6 5.4 
39 N N N N 13 12.8 7899 7499 134 140 0.8 1 13.2 13.5 22.9 23.6 18 20 5.3 4.5 6.2 6 
40 N N N N 12.8 11.9 8012 7612 130 139 0.9 1.1 12.8 13.3 25 25.6 19 18 5.1 5.2 5.4 5.3 
41 N N N N 11.9 10.1 8685 8285 126 135 0.8 0.9 14 13.7 24.8 25.1 22 18 5 5.2 6 6.2 
42 N N N N 13.1 10.7 8018 7618 128 138 1.1 1 13.5 13.9 24.4 23.8 20 19 5.4 5 6.2 5.4 
43 N N N N 12.7 9.8 8139 7739 119 130 0.8 1.1 12.5 13.6 23.9 24 20 21 5.5 5.2 5.5 5.3 
44 N N N N 9.9 10.2 8016 7616 116 137 1.0 1.1 12.8 13 25 25.5 18 22 5 5.5 5.2 5.5 
45 N N N N 10.1 11.11 7981 7581 140 138 1.1 0.9 13.9 14 24.5 24 18 20 4.5 5.2 6 6.2 
46 N N N N 12.7 13 8806 8406 129 133 0.8 1 13.2 13.6 25.5 23.6 19 21 5.2 5 6.2 5.3 
47 N N N N 11.7 12.4 7899 7499 130 139 0.9 0.8 13 13.9 23.2 25 22 20 5.58 5.5 5.3 5.5 
48 N N N N 10.8 12.1 8196 7796 126 140 1.0 1.1 12.7 14 23.8 25.2 20 19 5 4.5 6.1 6 
49 N N N N 10.2 11.8 7980 7580 128 137 1.1 1 12.5 12.9 24.6 24.4 21 18 5.3 5 5.5 6.2 
50 N N N N 11 12.1 7128 6728 131 139 0.9 1.1 13.1 13.5 24.2 25.3 18 21 4.5 5.2 5.1 6 
51 N N N N 12.3 12.7 8026 7626 129 140 0.9 1 14 13.3 24 25.2 19 22 5.2 5.4 6 6.3 
52 N N N N 12.9 12.5 7751 7351 139 130 1.0 0.8 13.6 13 25.2 25 22 20 5.5 5 6.2 5.5 
53 N N N N 11.8 11.3 8321 7921 127 133 1.1 1 12.9 12.8 25 25.4 20 22 5 5.1 5.4 6.2 
54 N N N N 10.2 11.1 7892 7492 135 138 0.9 1.1 14 13.9 25.3 25 18 20 4.5 5.4 5.2 5.5 
55 N N N N 11.1 12.9 8105 7705 136 140 0.8 1.1 13.8 13.3 25.1 23.8 21 19 5.2 4.5 6 6.1 
56 N N N N 10.4 11.6 8211 7811 132 133 1.0 1 12.9 14 22.8 24.5 19 20 5.3 5.2 5.5 6 
57 N N Hyperventilation Hyperventilation 12.6 12.7 7971 7571 129 120 1.1 1 12.5 13.5 23.6 25 22 20 4.5 5 6.2 6 
58 N N N N 12.1 12.3 7734 7334 131 138 0.9 0.8 13.5 13 23.4 25.2 18 22 5 5.5 5.2 6.2 
59 N N N N 12 13 7032 6632 125 132 0.8 1.1 13.2 13.9 25.2 23.9 21 20 5.5 5.3 5.4 69 
60 N N N N 13.1 12.7 7996 7596 129 139 1.1 1 13 14 22.8 24.2 22 20 5 5.4 6 5.4 
 
DOXOFYLLINE GROUP 
Investigations 
 
S.NO 
ECG CXR HB % TC RBS SERUM CERATININE BL UREA SGOT SGPT BT CT 
0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 
61 N N N N 11.9 12.3 8055 7655 140 135 1.0 0.9 12.9 13.8 23 25.2 19 21 5.4 5 6.2 5.5 
62 N N N N 11.2 11.9 8091 7691 129 136 1.1 0.8 12.7 13.4 23.2 25 21 22 5.1 5.2 5.5 5.3 
63 N N N N 12.1 11.2 7998 7598 132 139 0.9 0.8 13.1 13.8 24.8 25.2 20 22 5 4.5 5.2 6 
64 N N N N 12.9 13 7539 7139 138 127 1.0 1.1 13.3 14 25 24.8 22 20 4.5 5 6 6.2 
65 N N N N 10.8 11.6 8113 7713 130 123 1.1 1 13.5 12.9 25.2 23.9 19 18 5.4 5.2 5.3 6.1 
66 N N N N 11.7 12.2 7946 7546 140 129 0.8 1 12.8 12 25.1 25.2 20 19 5.5 5 5.5 6.2 
67 N N N N 12.1 11.8 8981 8581 133 120 1.0 0.8 12.7 12.9 22.9 24.8 18 20 5 5.3 6.1 5.5 
68 N N N N 11 12.1 7989 7589 126 132 0.9 1 12.9 13.3 24.6 25.2 20 18 4.5 5.5 6 6.2 
69 N N N N 9.8 11.2 8430 8030 131 139 0.9 0.8 12 13.2 25.2 25 22 20 4.5 5 6.1 55 
70 N N N N 10.1 12.4 7962 7562 129 120 1.1 0.9 12.9 13.5 24.8 25.2 20 19 5 4.5 5.5 6 
71 N N N N 11.8 13 8705 8305 137 140 1.0 1.1 14 13.3 22.8 23 19 18 5.5 5 6 6.2 
72 N N N N 9.2 10.8 8103 7703 129 134 1.1 1 13.3 13 25 24.5 19 20 5.2 5 6.2 5.5 
73 N N N N 10.5 11.2 8187 7787 130 136 0.9 1 12.2 13.8 24.6 24 22 21 4.5 5.2 5.3 6.1 
74 N N N N 12.1 13 7985 7585 122 131 0.8 1.1 12.8 14 23.2 24.8 21 22 5.3 4.5 5.5 6 
75 N N N N 11.9 12.5 8112 7712 129 120 1.0 1.1 13.2 13.6 22.8 23.6 18 19 5.4 5 6 6.3 
76 N N N N 9.8 10.9 7985 7585 139 140 1.0 0.9 14 13.1 25.2 25 20 19 5 5.4 5.2 5.5 
77 N N N N 11.3 12.2 8531 8131 137 133 0.8 1 13.5 13.8 25.4 25.6 21 22 5.5 4.5 6 6.2 
78 N N N N 12 12.7 7935 7535 138 129 1.1 0.9 13 12.8 25 25.8 19 20 5.1 5.4 5.5 5.2 
79 N N N N 11.1 12.3 7632 7232 140 131 1.0 0.8 13.1 13.6 22.8 24.8 22 19 5.5 4.5 6.2 6 
80 N N N N 10 11.8 8136 7736 128 136 1.1 0.8 12.8 13.7 23.1 22.8 18 21 4.5 5 6 5.5 
 
  
 DERIPHYLLINE  GROUP 
History and general examination 
 
S.NO. AGE SEX OCCUPATION DURATION OF ILLNESS AGE RAATDING FACTORS FAMILY HISTORY BMI 
1 58 M NIL 17 DUST NO 1 
2 42 M CATTLE REARING 5 DUST/CIGG SMOKE NO 2 
3 56 M NIL 10 NIL NIL 3 
4 38 M AGRI COOLI 20 DUST/COLD WEATHER YES(BA) 4 
5 59 M NIL 6 DUST/SMOKE NIL 5 
6 35 F WAITER IN COFFEE SHOP 2 DUST/AIR POLLUTION YES(BA) 6 
7 55 M SECURITY 5 COLD WEATHER NO 7 
8 40 F NIL 10 DUST/SMOKE YES(ALER) 8 
9 54 M NIL 7 DUST/SMOKE YES(BA) 9 
10 30 F AGRI COOLI 12 DUST/WEATHER YES(BA) 10 
11 58 M NIL 10 DUST/SMOKE NIL 11 
12 48 F NIL 5 DUST/SMOKE NIL 12 
13 50 M AGRICULTURE 3 DUST/SMOKE YES 13 
14 37 F CONTRUCTION COOLI 25 DUST/COLD WEATHER YES(BA) 14 
15 55 F AGRI COOLI 15 COLD WEATHER NIL 15 
16 56 F NIL 8 COLD WEATHER NIL 16 
17 32 F NIL 1 DUST/SMOKE YES 17 
18 24 M SECURITY 5 COLD WEATHER/ AIR POLLUTION NO 18 
19 36 F NIL 3 DUST/SMOKE YES(BA) 19 
20 55 F NIL 15 COLD WEATHER/DUST/SMOKE NIL 20 
21 50 F AGRI COOLI 10 DUST/AIR POLLUTION NIL 21 
22 42 F NIL 3 COLD WEATHER YES(BA) 22 
23 40 F BUILDING(CIVIL COOLI WORK) 10 DUST/AIR POLLUTION NIL 23 
24 30 F RECEPTIONIST 5 COLD WEATHER YES(BA) 24 
25 40 M CLERK 10 DUST NIL 25 
26 22 M STUDENT 7 DUST/COLD WEATHER YES(BA) 26 
27 55 M CATTLE REARING 15 DUST/SMOKE NIL 27 
28 40 M MECHANIC 8 DUST/AIR POLLUTION NIL 28 
29 38 F HOUSE MAID 5 DUST/SMOKE YES(BA) 29 
30 27 M CONTRUCTION LABOUR 3 DUST/SMOKE YES(BA) 30 
 
  
DERIPHYLLINE  GROUP 
History and general examination 
 
 
 
  
S.NO. AGE SEX OCCUPATION DURATION OF ILLNESS AGE RAATDING FACTORS FAMILY HISTORY BMI 
31 33 M DRIVER 4 DUST/COLD WEATHER NIL 26.2 
32 50 M SECURITY 7 DUST/COLD WEATHER NIL 22.4 
33 38 M GROSSORY SHOP 8 DUST/AIR POLLUTION NIL 24.8 
34 36 F HOUSE MAID 6 DUST/COLD WEATHER YES(BA) 26.4 
35 50 F - 2 - - 18.2 
36 26 M MECHANIC 2 DUST/AIR POLLUTION ALLERGY 17.6 
37 38 M TAILLOR 4 DUST - 23.1 
38 40 M CIVIL WORKER 7 DUST/AIR POLLUTION - 21.2 
39 45 F - 10 COLD WEATHER BA 19.3 
40 39 M PAINTER 7 DUST/AIR POLLUTION ALLERGY 20.4 
41 28 F HELPER IN SHOP 2 DUST/AIR POLLUTION ALLERGY 17.6 
42 52 M CATTLE REARING 9 DUST - 18.6 
43 41 F - 10 COLD WEATHER - 18.4 
44 46 F AGRI COOLI 12 DUST/COLD WEATHER - 19.6 
45 52 M CIVIL WORKER 8 DUST/AIR POLLUTION ALLERGY 20 
46 29 M VEG VENDAR 3 - - 21.7 
47 55 F - 12 COLD WEATHER BA 24.6 
48 49 M MECHANIC 7 - - 22.4 
49 52 M MILK VENDAR 15 DUST/AIR POLLUTION ALLERGY 24 
50 45 M CLERK 10 DUST - 22.3 
51 56 M - 20 COLD WEATHER BA 26.2 
52 28 F CIVIL WORKER 3 DUST - 16.2 
53 46 M SECURITY 10 COLD WEATHER BA 19.4 
54 38 M FACTORY WORKER 6 AIR POLLUTION - 17.6 
55 52 F CIVIL WORKER 12 DUST/AIR POLLUTION - 18.9 
56 37 M CARPENTER 6 DUST - 21.2 
57 48 F - 14 COLD WEATHER BA 26.3 
58 35 F HOUSE MAID 5 DUST - 30.2 
59 46 M HOTEL SERVER 9 COLD WEATHER ALLERGY 22.4 
60 53 M - 10 COLD WEATHER - 21.4 
DERIPHYLLINE  GROUP 
History and general examination 
 
S.NO. AGE SEX OCCUPATION DURATION OF ILLNESS AGE RAATDING FACTORS FAMILY HISTORY BMI 
61 55 F - 12 DUST/AIR POLLUTION ALLERGY 30.1 
62 48 F AGRI COOLI 11 DUST - 24.6 
63 49 M SHOP KEEPER 10 DUST - 28.2 
64 52 M CATTLE REARING 12 DUST - 18.4 
65 51 F SHOP KEEPER 12 AIR POLLUTION - 18.9 
66 49 M MILK VENDAR 10 DUST/AIR POLLUTION ALLERGY 21.2 
67 43 F - 8 COLD WEATHER BA 26.4 
68 42 M - 3 - - 21.3 
69 50 F HOUSE MAID 10 DUST/COLD WEATHER ALLERGY 18.6 
70 42 M OFF ATTENDER 7 DUST - 19.2 
71 38 F - 8 COLD WEATHER BA 21.4 
72 59 M - 12 DUST/COLD WEATHER - 22.1 
73 57 M - 15 DUST/COLD WEATHER BA 24 
74 48 M PETROL BUNK 7 DUST/AIR POLLUTION - 16.8 
75 58 M - 12 COLD WEATHER BA 21.4 
76 52 F HOUSE MAID 10 - - 19.6 
77 27 M MECHANIC 2 - - 18.3 
78 37 F FACTORY WORKER 5 DUST/AIR POLLUTION - 22.7 
79 43 M CONDUCTOR 8 DUST - 26.4 
80 41 M TEA SHOP 3 DUST - 20.1 
 
  BA-bronchial Asthma 
  BMI-Body 
 
 
  
DERIPHYLLINE  GROUP 
Efficacy and safety 
 
S.NO. ACT SCORE 
SUBJECTIVE 
RATING FVC % PREDECTED FEV 1 PEFR FEV 1/FVC ADRS 
0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 
 
1 16 18 20 20 60 70 70 80 55 78 80 82 50 68 74 79 68 70 74 76 64 68 76 78 PALPITATIONS 
2 18 20 20 22 60 70 80 80 50 72 82 84 60 66 74 76 64 68 70 72 60 62 70 72 HEADACHE 
3 18 20 20 21 50 60 70 80 45 68 70 80 58 60 74 78 58 62 68 74 58 62 70 74 TACHYCARDIA 
4 19 20 21 22 70 70 80 80 55 82 82 86 55 74 76 80 72 74 80 80 68 70 70 81 INSOMNIA 
5 16 18 18 20 50 60 60 70 60 64 70 82 59 62 70 76 60 64 68 72 59 60 68 70 NAUREA 
6 15 17 16 18 50 60 60 65 65 62 72 78 58 60 72 76 56 60 66 76 60 63 69 75 VOMITING 
7 15 16 16 18 50 50 60 70 50 64 70 79 58 62 69 73 60 64 70 78 62 64 74 80 TREMOR 
8 16 18 20 20 60 60 70 70 40 72 80 82 53 68 78 80 67 70 78 78 68 70 78 76 EPIGASTRIC DISCOMFORT 
9 18 18 20 22 60 60 70 80 50 72 78 82 62 64 72 74 62 64 70 72 62 64 72 74 HEADACHE 
10 18 18 20 20 60 70 70 80 45 72 76 80 62 64 74 76 60 64 72 74 60 64 70 74 NAUSEA 
11 16 16 18 20 50 60 60 70 64 68 72 74 52 64 72 78 58 62 68 76 60 63 70 76 TREMOR 
12 16 16 18 20 50 60 70 70 65 66 70 74 62 64 74 78 60 65 75 80 62 64 72 78 EPIGASTRIC DISCOMFORT 
13 18 18 20 22 60 60 70 80 54 74 79 82 64 66 78 80 68 70 76 78 64 68 76 78 TACHYCARDIA 
14 17 17 19 20 50 60 70 70 50 64 72 76 50 66 74 76 58 64 70 76 58 62 74 76 TREMOR 
15 17 16 20 20 60 50 70 70 64 58 72 77 66 60 74 78 64 60 72 76 64 60 76 78 HEADACHE 
16 16 18 18 20 50 60 60 70 56 62 64 76 58 64 67 76 58 60 64 78 60 66 68 76 NAUREA 
17 18 20 20 22 60 70 80 80 55 74 76 80 63 68 70 76 65 72 72 78 62 70 72 78 GIDDINESS 
18 16 17 18 20 60 60 70 80 62 64 74 78 62 64 74 76 64 66 72 76 62 65 72 77 EPIGASTRIC DISCOMFORT 
19 17 18 20 20 60 70 70 80 59 62 74 76 60 64 72 76 63 67 73 77 60 62 76 78 PALPITATIONS 
20 18 20 20 22 70 70 80 80 68 66 76 80 64 66 78 80 64 68 76 79 64 66 72 78 HEADACHE 
21 17 16 20 22 60 50 70 80 67 69 77 79 53 70 73 77 66 69 77 81 68 66 78 80 INSOMNIA 
22 18 20 22 22 70 80 80 90 68 74 76 84 68 76 78 82 70 76 78 84 70 76 77 86 NAUREA 
23 17 18 20 20 60 70 70 80 58 68 70 76 60 62 73 76 58 64 66 74 60 74 75 80 NAUREA 
24 18 18 20 22 70 70 80 85 70 70 76 78 65 70 76 79 64 66 71 74 64 70 74 77 GIDDINESS 
25 20 20 21 22 70 70 80 80 60 69 76 78 51 68 75 78 67 66 74 76 66 68 76 78 TREMOR 
26 18 20 22 22 70 70 80 80 56 66 74 76 52 66 73 78 64 66 76 78 66 68 72 78 TREMOR 
27 16 18 18 20 60 70 70 75 58 68 72 76 60 66 71 74 62 68 70 72 60 68 74 78 - 
28 18 16 18 20 70 60 70 80 68 58 70 78 53 60 72 76 66 58 70 76 67 58 74 78 PALPITATIONS 
29 18 18 20 22 70 70 80 80 55 68 78 80 62 68 77 78 68 67 74 78 67 69 76 78 HEADACHE 
30 20 18 20 20 70 60 70 70 68 58 68 72 50 56 70 72 66 56 70 72 68 60 72 74 INSOMNIA 
 
  
DERIPHYLLINE  GROUP 
Efficacy and safety 
 
S.NO. ACT SCORE 
SUBJECTIVE 
RATING FVC % PREDECTED FEV 1 PEFR FEV 1/FVC ADRS 
0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 
 
31 16 18 20 20 60 70 70 80 55 68 74 76 60 68 72 75 60 67 72 76 61 69 70 74 NAUREA 
32 18 18 20 22 70 70 80 80 64 72 74 76 52 74 76 80 68 70 76 78 70 71 78 79 HEADACHE 
33 18 18 16 20 70 70 60 80 68 70 58 78 66 68 60 79 67 70 61 78 69 72 60 80 VOMITING 
34 18 18 20 20 70 70 80 80 55 68 74 78 67 66 74 76 65 67 74 76 65 67 76 79 NAUREA 
35 16 17 20 19 50 50 70 60 76 81 83 82 51 70 75 80 57 66 68 74 60 65 72 80 NAUREA 
36 17 17 20 21 50 50 70 75 75 82 82 85 58 64 68 77 59 71 78 82 62 68 70 72 EPIGASTRIC DISCOMFORT 
37 16 16 20 21 50 50 70 75 78 80 81 873 63 62 77 79 65 68 71 75 58 63 75 79 - 
38 18 18 19 20 60 60 60 70 54 83 84 84 60 60 74 75 61 71 75 78 70 72 78 76 TREMOR 
39 16 17 20 20 50 50 70 70 66 82 83 82 61 65 69 76 56 68 68 72 65 68 70 74 - 
40 19 20 20 21 60 70 70 70 75 79 80 80 64 62 75 79 57 73 76 80 59 63 73 75 NAUREA 
41 16 16 17 18 50 50 50 60 61 80 80 80 58 60 71 80 56 66 68 76 58 62 71 72 - 
42 20 20 18 20 70 70 60 65 55 81 82 81 64 67 70 79 58 75 68 74 62 68 76 79 HEADACHE 
43 17 18 18 22 50 60 60 75 65 82 84 84 61 69 75 77 59 66 69 76 69 72 73 80 GIDDINESS 
44 16 20 22 22 50 65 75 70 55 79 80 80 63 63 77 80 65 69 71 81 65 68 74 75 PALPITATIONS 
45 17 18 20 20 50 60 65 65 60 80 81 83 59 65 72 78 58 68 70 74 70 72 76 78 TREMOR 
46 19 18 22 20 60 60 75 65 60 83 84 84 66 70 73 75 61 75 71 78 58 63 75 79 - 
47 16 16 18 20 50 50 60 65 65 81 83 81 61 62 79 78 67 71 74 75 59 62 71 73 NAUREA 
48 21 17 20 22 75 50 70 80 57 80 80 83 64 72 69 76 62 69 69 77 62 65 78 80 EPIGASTRIC DISCOMFORT 
49 20 20 22 22 70 75 80 80 65 82 83 82 63 65 70 79 57 66 67 72 60 68 75 78 TREMOR 
50 17 17 21 21 50 50 70 75 60 79 80 80 58 72 73 74 65 73 76 78 65 69 72 73 - 
51 17 19 20 22 50 60 70 70 76 82 84 85 61 64 70 80 58 75 69 76 62 68 76 81 PALPITATIONS 
52 16 18 18 20 50 60 60 70 55 80 80 80 64 74 75 75 56 69 77 82 69 72 73 75 HEADACHE 
53 18 20 20 22 60 65 65 80 60 81 82 83 59 65 68 74 61 68 70 75 58 62 71 72 - 
54 16 20 20 22 50 65 65 70 55 79 80 80 63 70 73 77 65 71 74 81 65 69 77 79 HEADACHE 
55 17 18 18 20 50 60 60 70 50 82 81 84 60 69 75 80 569 75 76 78 60 65 75 78 NAUREA 
56 18 20 22 21 60 65 75 75 65 79 80 80 58 72 71 78 61 71 70 74 59 66 76 79 INSOMNIA 
57 17 19 20 20 50 60 70 70 55 80 81 82 61 74 76 76 58 68 71 76 58 68 72 74 VOMITING 
58 17 19 21 21 50 60 70 70 81 79 80 80 65 65 72 74 67 73 69 75 62 65 70 76 - 
59 16 20 22 22 50 65 60 70 82 83 84 85 58 74 69 80 65 71 76 77 65 68 73 75 HEADACHE 
60 16 20 18 20 50 65 60 70 76 81 83 84 52 65 75 75 66 75 70 81 60 63 71 73 PALPITATIONS 
 
  
DERIPHYLLINE  GROUP 
Efficacy and safety 
 
S.NO. ACT SCORE 
SUBJECTIVE 
RATING 
FVC % 
PREDECTED FEV 1 PEFR FEV 1/FVC ADRS 
0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 
 
61 16 17 20 20 50 50 60 70 69 82 82 81 61 72 77 78 57 66 74 78 65 69 76 79 NAUREA 
62 16 18 21 22 50 60 70 80 66 80 81 83 59 69 78 79 65 76 77 77 62 65 78 80 - 
63 18 18 18 20 60 60 60 65 65 81 82 80 64 70 73 80 64 76 70 75 70 72 72 76 GIDDINESS 
64 16 17 18 20 50 50 60 65 50 82 83 82 61 72 74 77 68 68 69 74 65 68 74 76 EPIGASTRIC DISCOMFORT 
65 18 20 20 22 60 65 65 70 81 80 81 85 66 67 71 75 67 73 71 76 58 68 75 78 - 
66 18 18 20 21 60 60 65 70 55 79 80 80 58 74 78 80 66 71 77 82 70 72 76 79 TREMOR 
67 21 20 18 21 70 65 60 70 76 783 84 85 64 69 72 76 61 73 76 81 60 62 70 76 NAUREA 
68 19 17 20 21 60 50 65 70 56 81 84 85 59 65 71 77 59 66 74 75 58 68 78 81 - 
69 16 18 19 21 60 70 70 75 60 64 74 76 61 64 73 80 63 68 70 74 64 70 76 80 - 
70 16 18 18 20 50 50 60 70 60 70 79 79 58 63 71 76 60 68 74 80 62 68 77 79 NAUREA 
71 14 15 18 20 50 50 65 80 61 65 70 77 55 62 68 79 59 67 72 79 60 66 72 78 - 
72 18 16 20 21 60 75 70 75 58 62 77 79 63 65 70 77 56 62 70 78 58 62 74 76 TREMOR 
73 17 19 20 22 60 70 70 80 67 71 80 80 67 69 77 85 57 63 72 79 58 64 74 77 - 
74 18 20 20 21 50 50 60 70 62 66 72 76 65 65 73 74 59 65 74 78 60 65 75 80 - 
75 18 20 21 21 50 50 65 75 50 70 75 78 63 61 72 76 61 64 73 75 60 67 76 80 PALPITATIONS 
76 16 19 19 20 50 60 70 80 59 62 73 75 58 66 69 78 60 66 71 76 60 68 78 80 - 
77 17 18 18 20 50 65 70 75 60 64 70 78 65 68 72 79 58 67 72 74 58 63 70 76 - 
78 18 18 21 22 60 70 70 75 59 70 80 80 52 70 74 77 63 65 69 79 60 67 74 79 PALPITATIONS 
79 14 16 18 18 50 70 70 80 60 67 78 79 61 67 73 78 60 64 68 80 62 70 75 79 EPIGASTRIC DISCOMFORT 
80 16 18 18 20 60 75 70 70 61 63 76 78 51 70 76 80 58 62 70 81 58 64 76 80 - 
ACT- Asthma control test 
FVC-Force vital capacity 
FEV1- Forced expiratory volume in one sec 
PEFR-Peak expiratory flow rate 
ADRS- Adverse drug reactions 
 
  
DERIPHYLLINE  GROUP 
Cost effectiveness 
 
S.NO. 
DISTANCE 
FROM 
HEALTH 
FACILITY 
LOSS OF WAGES TRAVEL FOOD 
TOTAL ID INV 
DIRECT COSTS 
TMT OF 
ADR 
GRAND 
TOTAL PT ACP PT ACP PT ACP TMT TOTAL 
1 12 - NIL 20 - 20 - 40 
 
27.36 
 
- 67.36 
2 15 200 - 60 - 20 - 280 
 
27.36 
 
4.72 312.08 
3 12 - - 20 - 20 - 40 
 
27.36 
 
- 67.36 
4 24 50 - 75 - 50 - 175 
 
27.36 
 
- 202.36 
5 6 - - 20 - 20 - 40 
 
27.36 
 
12.13 79.49 
6 7 100 - 20 - 20 - 140 
 
27.36 
 
14.7 182.06 
7 30 100 - 80 - 100 - 280 
 
27.36 
 
- 307.36 
8 14 - - 40 - 20 - 60 
 
27.36 
 
2.95 90.31 
9 7 - - 20 - 20 - 40 
 
27.36 
 
4.72 72.08 
10 6 50 - 20 - 20 - 90 
 
27.36 
 
14.7 132.06 
11 15 - - 60 - 50 - 110 
 
27.36 
 
- 137.36 
12 20 - - 60 - 50 - 110 
 
27.36 
 
2.95 140.31 
13 40 150 YES 100 100 100 100 550 
 
27.36 
 
- 577.36 
14 10 70 - 20 - 20 - 110 
 
27.36 
 
- 137.36 
15 15 50 - 60 - 50 - 160 
 
27.36 
 
4.72 192.08 
16 14 - - 50 - 20 - 70 
 
27.36 
 
14.7 112.06 
17 18 - - 70 - 40 - 110 
 
27.36 
 
- 137.36 
18 13 100 - 60 - 50 - 210 
 
27.36 
 
2.95 240.31 
19 8 - - 40 - 20 - 60 
 
27.36 
 
- 87.36 
20 12 - - 60 - 20 - 80 
 
27.36 
 
4.72 112.08 
21 3 50 - 20 - 20 - 90 
 
27.36 
 
- 117.36 
22 8 - - 20 - 20 - 40 
 
27.36 
 
12.13 79.49 
23 14 100 - 100 - 50 - 250 
 
27.36 
 
14.7 292.06 
24 12 500 - 40 - 50 - 590 
 
27.36 
 
- 617.36 
25 12 500 - 50 - 50 - 600 
 
27.36 
 
- 627.36 
26 10 - - 20 - 20 - 40 
 
27.36 
 
- 67.36 
27 3 200 - 20 - - - 220 
 
27.36 
 
- 247.36 
28 15 200 - 50 - 20 - 270 
 
27.36 
 
- 297.36 
29 2 100 - 20 - - - 120 
 
27.36 
 
4.72 152.08 
30 1 100 - - - - - 100 
 
27.36 
 
- 127.36 
 
  
DERIPHYLLINE  GROUP 
Cost effectiveness 
 
S.NO 
DISTANCE 
FROM 
HEALTH 
FACILITY 
LOSS OF WAGES TRAVEL FOOD 
TOTAL ID INV 
DIRECT COSTS 
TMT OF 
ADR 
GRAND 
TOTAL PT ACP PT ACP PT ACP TMT TOTAL 
31 10 500 - 40 - 20 - 560 
 
27.36 
 
14.7 602.06 
32 6 100 - 40 - 20 - 160 
 
27.36 
 
4.72 192.08 
33 7 300 - 40 - 20 - 360 
 
27.36 
 
15.8 403.16 
34 15 100 - 60 - 20 - 180 
 
27.36 
 
14.7 222.06 
35 19 - 
- 
60 - 70 - 130 
 
27.36 
 
14.7 172.06 
36 2 200 - 20 - 20 - 240 27.36 2.95 270.31 
37 10 200 - 40 - 30 - 270 27.36 - 297.36 
38 13 100 - 40 - 30 - 170 27.36 - 197.36 
39 5 - - 20 - 20 - 40 27.36 - 67.36 
40 15 200 - 60 - 70 - 330 27.36 14.7 372.06 
41 4 100 - 20 - 20 - 140 27.36 - 167.36 
42 14 200 - 40 - 30 - 270 27.36 4.72 302.08 
43 5 - - 20 - 20 - 40 27.36 - 67.36 
44 17 50 - 60 - 70 - 180 27.36 - 207.36 
45 11 100 - 40 - 30 - 170 27.36 - 197.36 
46 16 100 - 60 - 70 - 230 27.36 - 257.36 
47 15 - 500 60 60 70 70 760 27.36 14.7 802.06 
48 6 200 - 30 - 20 - 250 27.36 2.95 280.31 
49 9 100 - 30 - 20 - 150 27.36 - 177.36 
50 16 500 - 60 - 70 - 630 27.36 - 657.36 
51 20 - 400 70 70 100 100 640 27.36 - 667.36 
52 3 70 - 20 - 20 - 110 27.36 4.72 142.08 
53 17 100 - 60 - 70 - 230 27.36 - 257.36 
54 8 150 - 30 - 20 - 200 27.36 4.72 232.08 
55 5 70 - 20 - 20 - 110 27.36 14.7 152.06 
56 12 200 - 40 - 30 - 270 27.36 - 297.36 
57 20 - - 70 - 100 - 170 27.36 15.08 212.44 
58 20 100 - 70 - 100 - 270 27.36 - 297.36 
59 17 100 - 60 - 70 - 130 27.36 4.72 162.08 
60 5 - - 20 - 20 - 40 27.36 - 67.36 
 
  
DERIPHYLLINE  GROUP 
Cost effectiveness 
 
S.NO 
DISTANCE 
FROM 
HEALTH 
FACILITY 
LOSS OF WAGES TRAVEL FOOD 
TOTAL ID INV 
DIRECT COSTS 
TMT OF 
ADR 
GRAND 
TOTAL PT ACP PT ACP PT ACP TMT TOTAL 
61 11 - 300 40 40 30 30 440 27.36 14.7 482.06 
62 7 50 - 30 - 20 - 100 27.36 - 127.36 
63 3 250 - 20 - 20 - 290 27.36 - 317.36 
64 14 200 - 40 - 30 - 270 27.36 4.62 301.98 
65 18 250 - 60 - 70 - 380 27.36 - 407.36 
66 15 100 - 60 - 70 - 230 27.36 - 257.36 
67 4 - - 20 - 20 - 40 27.36 14.7 82.06 
68 10 100 - 40 - 30 - 170 27.36 - 197.36 
69 20 100 70 100 290 27.36 - 317.36 
70 10 150 40 40 230 27.36 12.13 269.49 
71 6 - 200 30 30 20 20 300 27.36 - 327.36 
72 1 - 100 20 20 20 20 180 27.36 - 207.36 
73 8 - 30 20 50 27.36 - 77.36 
74 19 200 60 70 330 27.36 - 357.36 
75 5 - 300 20 20 20 20 380 27.36 - 407.36 
76 7 100 30 20 
 
150 27.36 - 177.36 
77 4 200 20 20 
 
240 27.36 - 267.36 
78 12 150 40 30 
 
220 27.36 - 247.36 
79 17 300 60 70 
 
430 27.36 - 460.31 
80 19 150 60 70 
 
280 27.36 - 307.36 
PT-pationt 
ACP-accompaning person 
ID-indirect cost 
TMT-treatment 
ADR-adverse drug reaction 
ECG-electro cardio graphy 
CXR-chest ex-ray 
HB-hemoclobin 
TC-total count 
RBS-random blood sugar 
BT-bleading time 
CT-clotting time 
 
  
DERIPHYLLINE  GROUP 
Investigations 
 
S. 
NO 
ECG CXR HB % TC RBS SERUM  CREATININE BL UREA SGOT SGPT BT CT 
0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 
1 N N N N 10.1 10.2 8421 7804 120 110 0.8 0.9 1.4 14.6 23.6 24 22 20 5 4.9 6 6.2 
2 N N N N 11.2 11.3 8620 7610 130 120 0.9 0.7 1.45 13.9 23.8 26 20 21 5.2 5.1 5.6 5.6 
3 N N N N 10.6 10.8 7410 7816 116 118 0.8 0.9 12.2 12.8 23.6 24.2 19 20 5.1 5 5.6 6 
4 N N N N 11.3 11 6410 7602 124 126 0.9 1 13.2 14 25.1 25.6 20 22 5.3 5.2 6.1 6.2 
5 N N N N 10 10.2 8141 6234 132 134 0.9 0.8 13.6 13.4 24.2 24.8 19 20 5.2 5.1 6.1 5.6 
6 N N N N 9.4 9.6 8940 7016 130 120 0.8 0.9 13.4 13.6 22 23.4 20 21 5.4 5.3 6 5.4 
7 N N N N 11 11.2 8412 8623 110 120 0.7 0.7 12.8 12.9 24 23.6 19 23 5.3 5.2 6.2 6.3 
8 N N N N 9.6 9.4 5162 7201 130 120 0.8 0.8 12.9 13.2 23 24.2 18 19 5 4.9 5.6 5.4 
9 N N N N 11 11 6238 6381 116 141 0.9 1 13.8 14.4 23.4 25.2 19 21 5.2 5.1 6.2 5.4 
10 N N N N 9.8 9.6 7162 7816 120 121 0.78 0.9 13.4 14 23.6 24.4 22 23 5 4.9 6.3 6 
11 N N N N 10.2 10.4 6841 7620 110 116 0.8 0.8 14 13.2 24.2 25.2 20 22 5.1 5 5.4 6.2 
12 N N N N 9.6 9.8 7810 7600 113 118 0.7 0.9 12.2 12.8 25.1 25 21 23 5.4 5.3 6 5.6 
13 N N HYPER VENTILATION 
HYPER 
VENTILATION 11.2 11 7160 8100 114 125 0.8 0.7 13.4 13.6 23.7 24.5 23 24 5.3 5.2 6.2 6.1 
14 N N N N 8.6 8.8 8600 9000 126 100 0.8 0.9 14.4 12.9 23 23.4 19 21 5.3 5.2 5.6 5.4 
15 N N N N 9.2 9.4 8916 6780 104 115 0.9 1 13 13.7 22.6 23.6 18 20 5 4.9 6.1 6 
16 N N N N 8.8 9 7416 7818 114 127 0.7 0.9 12.8 14.1 23.2 24.2 20 22 5.2 5.1 1 6.2 
17 N N N N 10.1 10 7618 7114 116 120 0.9 0.8 13.6 13.8 24.4 25.1 19 20 5.1 5 5.4 5.6 
18 N N N N 10.4 10.2 8617 7918 128 110 0.9 0.8 12.9 15 23.4 24.3 20 21 5 4.9 6 6.1 
19 N N N N 10 9.8 7148 7618 109 117 0.8 0.9 13.7 14.4 23.6 24.6 22 23 5.4 5.3 6.2 5.4 
20 N N N N 9.6 9.8 7418 7614 110 120 0.8 0.7 12.9 14.2 24.2 24.6 18 19 5.3 5.2 6.1 5.4 
21 N N N N 9.8 10 8410 7914 120 116 0.8 0.8 14 14.2 25.2 23.6 20 18 5 4.9 5.6 6.3 
22 N N N N 8.8 8.6 8619 8810 118 132 0.9 0.1 14.4 13 22.9 23.4 20 22 5.2 5.1 5.4 6 
23 N N N N 10.1 10.2 7816 7610 130 121 0.7 0.8 12.6 12.8 22.8 23.6 22 24 5 4.9 6.3 6.2 
24 N N N N 9.6 9.8 8810 8901 108 119 0.8 0.9 12.8 13.6 23.6 24.2 20 23 5.2 5.1 6.3 6.1 
25 N N N N 10.2 10 8671 7819 116 131 1 0.8 14.1 12.9 24.9 25.2 21 22 5.1 5 6 5.4 
26 N N N N 11 11 7610 6901 120 107 0.9 0.8 13.4 13.7 23.4 24 23 21 5.4 5.3 6.2 5.4 
27 N S..TACHYCARDIA HYPER VENTILATION 
HYPER 
VENTILATION 11.2 12 9700 9000 130 114 0.7 0.9 12.8 14.6 23.6 24.2 19 21 5 4.9 6.1 5.4 
28 N N N N 10.6 11 7900 9301 113 120 0.8 0.7 13.6 14.7 24.2 22.8 20 21 5.2 5.1 6.3 6 
29 N N N N 10.8 11 8610 8510 114 121 0.8 0.8 13.9 14.1 25 23.4 23 22 5.4 5.3 6.3 6.2 
30 N N N N 9.6 9.4 6714 7612 115 129 0.9 0.8 14.2 13 22.8 23.6 19 20 5.4 5.3 5.4 6.1 
 
DERIPHYLLINE  GROUP 
Investigations 
 
S. 
NO 
ECG CXR HB % TC RBS SERUM  CREATININE BL UREA SGOT SGPT BT CT 
0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 
31 N N N N 10.6 10.4 6718 7160 122 106 0.7 0.7 13.7 12.8 23.8 24.2 20 21 5.2 5.1 6 
 
32 N N N N 10.2 10.4 8601 8701 128 123 0.7 0.8 12.9 13.6 23.4 23.8 20 21 5.1 5 6.2 
 
33 N N N N 10.1 10 8174 8410 112 127 0.9 0.9 14 13.6 24.2 25 21 23 5 4.9 6.1 
 
34 N N N N 9.6 9.8 7612 8610 124 126 0.8 0.9 12.8 13 23.6 24 22 20 5 4.9 6.2 
 
35 N N N N 10.2 10.6 9620 9612 120 110 0.8 0.9 14.2 14.6 23.2 24.1 21 20 5 4.9 6.1 
 
36 N N N N 9.6 9.8 7420 6986 119 117 0.7 1.1 12.2 13.5 22 25.2 18 20 5.3 5.2 5.4 
 
37 N N N N 10.1 11.6 8724 9426 112 127 0.9 1 12.5 13.7 23.6 26 19 21 5 4.9 6 
 
38 N N N N 10.2 11.2 8626 7852 124 116 0.7 0.9 12.2 13.9 24.2 25.6 19 19 5 4.9 5.6 
 
39 N N N N 8.6 8.8 8567 9784 121 127 0.9 1 12.5 13.7 22.8 24.3 20 22 5.1 5 5.6 
 
40 N N HYPER VENTILATION 
HYPER 
VENTILATION 11.2 9.6 9486 9674 117 116 0.7 0.8 12.8 13.2 23.4 23.6 22 21 5.1 5 6  
41 N N N N 11 10.1 9847 9658 127 119 0.9 0.9 13.5 13.7 24.2 24.2 22 20 5.1 5 5.6 
 
42 N N N N 10.1 11.2 8859 8721 118 127 0.8 1.1 12.8 13.2 23.8 23.2 19 20 5 4.9 5.4 
 
43 N N N N 9.6 10.2 8841 8970 127 121 1.0 0.9 12.5 13.5 22 24.1 19 18 5 4.9 5.6 
 
44 N N N N 10.2 10.1 9216 6920 119 112 0.8 0.9 12.2 13.2 23.6 25.2 21 20 5 4.9 5.4 
 
45 N N N N 8.8 11.2 9784 8741 127 124 0.9 1 13.5 13.7 22.6 25.6 19 23 4.6 4.5 5.6 
 
46 N N N N 10.3 12 6129 7840 127 121 0.7 0.9 13.9 14.2 23.8 22.8 22 22 5.1 5 6 
 
47 N N N N 8.6 10 8641 8649 120 117 0.7 0.9 12.2 12.8 23.9 24.9 21 23 5.1 5 5.4 
 
48 N N N N 10.1 11.2 6947 9920 112 119 0.8 0.9 13.5 14.2 24 25.6 18 19 5.2 5.1 6 
 
49 N N N N 8.6 8.8 7469 8497 124 127 0.7 0.8 13.5 14.1 23.6 26 21 20 5.1 5 5.6 
 
50 N N N N 10 9.6 7849 8421 121 118 0.7 0.9 12.8 13.2 23.2 24.6 21 23 4.9 4.8 6 
 
51 N S..TACHYCARDIA N N 10.1 10.2 9290 6482 117 119 0.9 1.1 12.5 13.5 23.6 24.1 20 22 5 4.9 5.4 
 
52 N N N N 8.9 9.2 9762 8217 127 116 0.8 1 14.2 13.9 23.5 25.6 18 19 5.2 5.1 5.5 
 
53 N N N N 9.7 11.2 7614 6148 115 127 0.8 0.9 12.2 12.8 23.6 25.2 20 21 5 4.9 6 
 
54 N N N N 9 8.8 8810 7482 117 118 0.9 1.1 12.8 13.2 22 25 19 23 5 4.9 5.6 
 
55 N N N N 9.6 10 8470 7621 119 120 1.0 0.8 15.5 14.1 23.9 25.6 21 22 5.3 5.2 5.5 
 
56 N N N N 10.2 11.2 9847 9421 127 112 0.7 0.9 12.2 12.8 23.8 24.8 21 23 5.1 5 5.4 
 
57 N N N N  10.1 9486 8641 118 124 0.9 1.1 12.5 13.7 21.6 23.2 22 18 5 4.9 5.6 
 
58 N N N N 8.8 10 7841 8490 117 121 0.8 0.9 12.8 13.2 23.6 24.1 20 19 5.1 5 5.4 
 
59 N N N N 8.6 9.7 9714 9947 127 119 0.9 1 13.9 14.3 23.8 25.2 21 20 4.9 4.8 5.4 
 
60 N N HYPER VENTILATION 
HYPER 
VENTILATION 10.4 10.1 8914 8610 118 127 1.1 1.1 12.2 13.9 22 25.6 21 23 5.1 5 5.5  
 
 
DERIPHYLLINE  GROUP 
Investigations 
 
S. 
NO 
ECG CXR HB % TC RBS SERUM  CREATININE BL UREA SGOT SGPT BT CT 
0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 
61 N N N N 9.7 9.6 8771 7620 120 118 0.9 0.8 12.2 12.8 24.2 25.2 20 22 4.6 4.5 5.6 6.2 
62 N N N N 10 10.2 9619 7612 112 119 0.7 0.9 12.5 13.8 23.6 25.6 18 23 5.1 5 6 6.2 
63 N N N N 11.2 11.4 8912 9753 124 127 1.1 1 12.5 13.7 23.2 24.6 19 23 5.1 5 5.6 6.1 
64 N N N N 8.6 8.8 7810 8442 121 117 0.7 0.9 14.4 13.9 23.6 24.1 20 18 5 4.9 5.5 6.2 
65 N N N N 11.2 11.6 9846 8898 124 120 0.8 0.9 13.5 12.8 23.6 25.2 22 21 5.2 5.1 6 6.3 
66 N N N N 10.2 11.2 8818 9614 119 112 0.9 0.9 13.9 14.6 22.8 24.6 18 20 5.4 5.3 5.6 6.1 
67 N N N N 9.6 8.8 9626 7941 117 124 0.9 1 14.2 14.2 24.6 24.1 19 21 5 4.9 5.6 6 
68 N N N N 10.1 11.1 8421 8561 128 120 0.7 0.8 12.6 13.7 22 25.2 21 23 5.1 5 6.1 6.3 
69 N N N N 8.6 10.6 8411 7128 125 130 0.9 1.1 12.4 13.4 23.6 22.8 20.6 20 5 4.9 5.4 5.6 
70 N N N N 10.6 9.8 8617 9759 135 126 1.0 0.9 12.5 13.7 23.3 23.6 20.3 21.1 5.2 5.1 5.8 5.4 
71 N N N N 10.4 12.4 8754 9688 129 117 0.8 1 12.6 13.6 23.1 23.8 20.1 19 5 4.9 6 6.2 
72 N N N N 11.6 10.8 9771 8712 123 134 0.8 1 13 14.1 23.8 23.3 20.8 20 5.1 5 5.6 6.1 
73 N N N N 12 8.8 8744 8941 118 124 0.9 1.1 12.9 14.3 23.3 23.7 20.3 18 5.3 5.2 6.2 6 
74 N S.TACHYCARDIA N N 9.4 11 8676 9781 133 125 0.8 0.9 13.5 12.6 22.9 23.6 20.9 21 5 4.9 5.6 6.3 
75 N N N N 11.4 10.2 9942 8418 127 122 0.8 0.9 13.1 13.8 22.8 23.3 20.8 22 5.1 5 5.4 6 
76 N N HYPER VENTILATION 
HYPER 
VENTILATION 8.9 10.4 8641 8917 119 131 1.0 1.1 13.2 14 23.1 23.5 20.1 20 5.3 5.2 6 0.8 
77 N N N N 11.2 12.4 8110 9361 136 121 1.1 1.2 13.1 14.2 23.6 24.2 20.6 19 5.2 5.1 5.6 6.3 
78 N N N N 10.6 9.1 8916 8810 126 132 0.9 1 12.8 13.8 23.3 21 20.3 18 5.3 5.2 5.6 6 
79 N N N N 10.8 10.2 9612 7104 113 128 1.0 1 12.6 13.4 23.4 24 20.4 20 5.2 5.1 6 6.3 
80 N N N N 9.6 9.8 7745 8628 121 140 0.8 1 12.4 13 24 23.1 20 22 5 4.9 5.8 6.2 
 
 
   
 
